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CHAPTER 
1 
INTRODUCTION 

Introduction 
Research into the causes of hereditary hearing loss and hereditary deafness 
was initiated in the second half of the nineteenth century. In this period, the 
first reports appeared on a number of fairly common hereditary syndromes 
with hearing loss as one of the characteristic symptoms. 
The autosomal recessive hereditary syndrome with the chief symptoms of 
deafness and blindness, which was later named after the Scottish 
ophthalmologist, Charles Usher, was the first hereditary syndromal disease 
with deafness to be described and it is also the subject of this thesis. This 
syndrome is characterised by congenital deafness or hearing impairment in 
the inner ear and eventual blindness due to retinitis pigmentosa. 
The famous Berlin ophthalmologist, Albrecht von Graefe1, was the first to 
describe this syndrome in three "deaf-blind" brothers from one family. Only a 
few years previously, the ophthalmoscope had become available for clinical 
application and as a consequence, his nephew, Alfred Graefe, realised at his 
Berlin clinic that the congenital deafness in these three children, together with 
his diagnosis of co-existing retinitis pigmentosa, must be the result of a 
hereditary pattern. An in-depth description of this syndrome was published in 
1861 by the Berlin ophthalmologist, Liebreich2. He performed a systematic 
examination of the deaf population in Berlin, which totalled 341 persons, and 
was amazed by the relatively high incidence of retinitis pigmentosa among 
the deaf, particularly in those with a Jewish background. Moreover, the high 
consanguinity ratio among the parents of the affected persons was striking. 
The incidence of congenital deafness among the Jews in Berlin at that time 
(1:368) was higher than among the remaining population (1:1477). It was 
understood that the higher consanguinity ratio among Jews played a role in 
this. 
Liebreich's systematic study formed a model for other studies on the 
prevalence of retinitis pigmentosa in patients with congenital deafness. 
Examples of this are studies by Adler (1876)3, Lee (1883)4 and later in the 
Netherlands, the studies by De Wilde (1913 and 1919)5·6. In 1907, 
Hammerschlag7 confirmed the previous German findings of a high frequency 
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of the disorder in his study on the Jewish community in Vienna; this was also 
confirmed later by De Wilde (1919)6 in the Netherlands. In 1914, the Scottish 
ophthalmologist, Charles Usher8 from Aberdeen, published the first 
description of this disease in English. He had conducted a survey on deaf 
persons with visual problems in the U.K. Usher also mentioned this condition 
in his Bowman lecture in 19359, which was entitled "On a few hereditary eye 
affections". As a result, his name became an eponym for the syndrome, 
especially in the ophthalmological literature, although Liebreich probably had 
a considerably greater claim to this privilege. 
Studies on the Usher syndrome were subsequently conducted from two 
different perspectives. On the one hand, populations with congenital deafness 
were examined systematically to discover the possible causes of deafness. The 
results of several surveys on large groups of deaf persons performed on a 
national scale (Uchermann 1892 in Norway10; Henning 1928 in Sweden"; 
Lindenov 1945 in Denmark12) concurred in finding a relatively high frequen-
cy of retinitis pigmentosa among deaf persons. Remarkable monographs on 
the Usher syndrome include those by Hallgren (1959)13 and Nuutila (1970)14 
which describe complete nation-wide observations in Sweden and Finland, 
respectively. 
From the other perspective, data were being collected in the field of 
ophthalmology from patients with retinitis pigmentosa (Nettleship 1907-
190815, Usher 19148, Bell 192216, Von Wibaut 193117 and Kjerrumgaard 
194818) and records were kept of how many of these patients were also 
hearing impaired. The pattern of inheritance of retinitis pigmentosa can be 
autosomal dominant or autosomal recessive, but it may also be sex-linked19. 
The methodology of such research attempts, although out of necessity, was 
somewhat unsatisfactory because persons with retinitis pigmentosa did not 
form a socio-educational isolate and were not readily accessible for 
examination, unlike the deaf in many countries20. 
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In 1966, Kloepfer et al21 reported a very interesting situation among the 
Acadian population in the bayous of Louisiana. The population comprised 
57,000 persons and no less than 44 cases had the Usher syndrome. This 
represented a substantial proportion (about 40 per cent) of all the persons in 
the population with profound childhood deafness. This prevalence was much 
higher than any other figure reported for this condition in various 
populations. Fraser (1976)20 therefore assumed that a proportion of the 
founders of this isolated and inbred population, had carried the abnormal 
allele from their original home in Canada. Consequently, as the population 
grew in their new domicile, the condition reached its high level of 
prevalence. It is true that over 100 years ago, the French Acadian migrated to 
the bayous of Louisiana from Quebec and until the Second World War they 
remained genetically isolated. The Acadians were originally from the 
Normandy region of France. Fraser (1976)20 also noted that the Swedish 
survey by Hallgren (1959)13 and the Finnish survey by Nuutila (1970)14 
showed a very uneven prevalence of cases with Usher syndrome in the 
various provinces of these countries. This suggested that the number of 
original mutations was limited and that, as was also the case with the Acadian 
population, subsequent population growth led to an unequal dissemination of 
the condition. Both Hallgren13 and Nuutila14 noted that in the provinces with a 
high prevalence, there was a concentration of cases in a restricted number of 
communes which often had the characteristics of breeding isolates. These 
observations on the Acadian population in Louisiana were later confirmed by 
gene linkage studies to chromosome 11 (USH1C)22 and it has been shown 
that this inbred population originally migrated from France to Canada and 
subsequently went south to Louisiana (USA). Recent gene linkage studies in 
Finland have also successfully linked patients, who mainly originated from 
the eastern part of the country, to chromosome 3q (USH3). This delineates a 
distinct type of the Usher syndrome called type III, with progressive hearing 
loss23. 
In Western Europe, the prevalence of early childhood deafness (up to the age 
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of 5 years) with a minimum hearing loss of 40 dB in the best ear at the 
frequencies 0.5, 1 and 2 kHz, is estimated to be 1.27 per 1000 births24. 
Parving25 mentioned that the prevalence of congenital or early acquired 
hearing loss in Denmark was 1.5/1000 with a hearing loss of > 25 dB 
(average at 0.5-4 kHz) in the best ear. Martin et al26 estimated that in Western 
Europe, the incidence was 1 in 1000 if the hearing loss in the best ear was 
greater than 70 dB. 
In the school study by Van Rijn27 the distribution of the groups with a 
hearing loss in the best ear of between 35 dB and 70 dB is noteworthy. We 
can conclude that the figures presented by Davis and Parving24, Parving25 and 
Martin et al26 are in agreement. The prevalence of the Usher syndrome was 
estimated to be 3.0 per 100,000 in Scandinavia13"1 and 4.4 per 100,000 in the 
United States28. The prevalence of the Usher syndrome among persons with 
congenital deafness or hearing impairment varies strongly, which is illustrated 
in the studies by Kloepfer et al (1966)21 en Vernon (1969)29. It is generally 
accepted that the percentage varies between 3-5%. The Usher syndrome 
constitutes approximately 50% of deaf-blindness in adulthood. 
Julia Bell (1922)16 documented familial disease and published an 
accumulation of pedigrees under the title "Treasury of human inheritance". 
She was the first to recognise clinical heterogeneity of the Usher syndrome. 
Bell identified 96 cases of retinitis pigmentosa associated with congenital 
deafness (variable degree of residual hearing and at least some speech 
facility), or deaf-mutism (profound hearing loss with unintelligible speech) 
and reported a prevalence of 10.4% in her total series of 919 persons with 
congenital deafness. Therefore, variation in the severity of congenital 
sensorineural hearing loss in patients with retinitis pigmentosa was apparent 
even in the initial reports on Usher syndrome. Hallgren (1959)13 emphasized 
that there were at least two different clinical types that may be caused by two 
different genes. 
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Merin et al (1974)30 divided the syndrome into four clinical entities: 
Type I: Profound congenital deafness, practically no vestibular response to 
caloric or rotatory excitation and the onset of retinitis pigmentosa 
by 10 years of age. This type is by far the most common and 
affected individuals have normal mental development without any 
neurological deficit. 
Type II: Slowly progressive, moderate to severe congenital deafness with 
normal vestibular function and the onset of retinitis pigmentosa in 
the early twenties (much milder functionally than type I) occurring 
in approximately 10% of cases. 
Type III: Complete congenital deafness combined with retinitis pigmentosa 
manifesting itself at about puberty in addition to mild vestibular 
ataxia. 
Type IV: Phenotypically identical to type I, but with mental retardation. 
Types III and IV are considered to be very rare, comprising less 
than 1 % of cases. 
In their famous book on Genetic and Metabolic Deafness, Konigsmark and 
Gorlin (1976)31 did not take the opportunity to split the Usher syndrome into 
subtypes, but they did mention that there was evidence that expressivity could 
be quite variable. They reported that the syndrome is characterized by 
congenital moderate to severe sensorineural hearing loss, vestibular 
hypofunction and slowly progressive retinitis pigmentosa. Some of the 
patients reported on by Hallgren (1959)13 showed mental deficiency and later 
psychosis. The two authors considered it possible that the Usher syndrome 
was a genetic heterogeneity and that the kindred described by Hallgren 
represented a separate entity. 
15 
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On the basis of an extensive literature study, Davenport and Omenn (1977)32 
originally divided the Usher syndrome into 4 types, but later reduced this to 
3: 
Type I: Profound congenital deafness with the onset of RP before puberty. 
Present in a total of 90% of all cases. 
Type II: Moderate to severe hearing loss from birth with the onset of RP 
after puberty. Present in a total of 10% of all cases. 
Ataxia was described in up to 90% of persons affected by type I, 
but only occasionally in persons with type II. This was probably 
labyrinthine in origin and reflected severe inner ear damage. 
Type III: Progressive hearing loss and RP may constitute a third category. 
Type IV: Originally, type IV was considered to have an X-chromosome-
linked recessive inheritance pattern. This was based purely on the 
observation of two pairs of affected brothers who were related 
maternally as first cousins, once removed; only the proband was 
examined by the authors (personal communication Bateman33 with 
Davenport). Type IV was later redefined. 
Gene linkage and isolation in the Usher syndrome 
At least six loci have been identified for the Usher syndrome: three for type 
I, two for type II and one for type III (Table 1). 
The Usher syndrome type 1A gene was the first to be localised, on 
chromosome 14q35. On the basis of statistical tests, genetic heterogeneity was 
demonstrated, which suggested the possibility that linkage was being obscured 
by the involvement of two or more different genes. Further research showed 
that not all Usher type I patients could be linked to chromosome 14q. The 
majority of families linked to 14q came from the same region, known as the 
Poitou-Charentes region of France. Since then, the gene has been referred to 
as USH1A. An analysis by the Usher syndrome consortium on the families 
they had collected data on36 could not demonstrate gene linkage. This 
suggests that the gene localised on 14q is uncommon outside the Poitou-
Charentes region. 
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Table 1: Classification of the Usher syndrome by type and subtype 
Syndrome Gene Location References 
Usher I USH1A 14q 
USH1В 11 q (myosin VII A gene) 
USH1C l ip 
Usher II USH2A lq 
USH2B unknown 
Usher III USH3 3q 
Kaplan et al 199235 
Kimberling et al 199237 
Smith et al 199238 
Bonne-Tam i г В et al 199439 
Weston et al 19954ü 
Keats et al 199422 
Kimberling et al 1990" 
Lewis et al 199042 
Pieke Dahl et al 199343 
Sankila et al 199523 
At a later date, these families who had a different type of Usher type I and 
who came from two different regions, could be linked to chromosome 11. 
The gene linked to 1 lq is called USH1B37·38·39 and the gene linked to 1 lp is 
called USH 1С22. So far, families with USH 1С have only been found in the 
French Acadian community of southern Louisiana. The Acadians were 
originally from the Normandy region of France; there is no evidence that they 
share ancestry with the families from Poitou-Charentes who show linkage to 
14q. 
Fishman et al (1983)34 separated the Usher syndrome into two different types 
of Usher patients. 
Type I: Onset of nyctalopia within the first decade or at the beginning of 
the second decade of life, profound hearing loss (100 dB or more) 
and vestibular hypoactivity to caloric stimulation. All the patients 
showed marked impairment of the peripheral visual fields. 
17 
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Type II: Nyctalopia apparent later in life (in the latter part of the second 
decade or at the beginning of the third decade of life), moderate 
(40-60 dB) to very occasionally severe (90 dB) hearing loss and 
normal vestibular sensitivity. Less severe peripheral visual field 
loss than in the patients with type I. 
Although three gene localisations have been established for Usher syndrome 
type I, no gene linkage has been achieved for some families with the Usher 
syndrome. Therefore, it is likely that there are more types of Usher type I. 
Recently, the USH1B gene has been identified. This gene codes for the 
protein myosin VIIA40. 
Usher syndrome type II has been localised on chromosome lq3241,42. A 
number of families with Usher syndrome type II did not link to chromosome 
l43'44, or to chromosomes l ip, l lq or 14q. The syndrome linked to 
chromosome lq32 is known as USH2A. The other variation of Usher type II 
is called USH2B. 
Very recently, Usher type III has been linked to chromosome 3q in a Finnish 
population, the USH3 locus23. 
Audiological characteristics of the Usher syndrome 
Clinically, Usher type I can be distinguished from type II on the basis of the 
severity of the hearing loss. Type I patients are profoundly deaf, whereas type 
II patients are "hard of hearing". It is not yet clear whether there is any 
overlap in the level of hearing loss between type I and type II. The 
audiogram of type II patients is characterised by perceptive hearing loss that 
deteriorates at higher frequencies. The hearing loss associated with types I 
and II is congenital. It is assumed that the hearing loss in type II patients is 
stable. 
Until recently, there has been some hesitancy about the existence of the Usher 
18 
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syndrome type III. This hesitancy has now disappeared owing to gene linkage 
to chromosome 3q23. Type III is characterised by progressive hearing loss. A 
short while ago, the first descriptions appeared about the level of hearing loss 
in relation to age. Pakarinen et al45 found a mean progression in hearing loss 
of about 21 dB per decade in their patients. The progression in their group 
occurred in early childhood in a fairly short period, or in middle age over a 
longer period. So far, this syndrome has mainly been diagnosed in Finland. 
Vestibular characteristics 
The Usher syndrome type I can be distinguished from type II on the basis of 
vestibular areflexia in type I. The vestibular reflex is a reliable means of 
distinguishing between the two types. Vestibular testing of a deaf child can 
throw doubt on an early diagnosis of Usher type I if he or she demonstrates a 
vestibular reflex. A normal electroretinogram (ERG) does not exclude the 
later development of the Usher syndrome in young children. In 1959, the first 
report appeared on an unsteady gait in some Usher syndrome patients by 
Hallgren13; he referred to this as vestibular ataxia. Although it was assumed 
that the abnormal gait was caused by vestibular areflexia, later research 
showed that there were no cerebellar symptoms in the patients with Usher 
type I and type II described by Moller et al from Sweden46. The vestibular 
areflexia seemed to be congenital or had an onset at a very early age because 
compared to other children, Usher type I patients were late to sit, stand and 
walk. Vestibular response to testing is known to be normal in type II, redu-
ced/absent in type I13·29·46·47 and normal47'48-49 or normal/hypoactive in type 
III50·51. 
Ophthalmological characteristics 
Retinitis pigmentosa (RP) encompasses a large heterogeneous group of retinal 
abnormalities. The clinical characteristics of RP are night blindness, 
sometimes before school age and progressive narrowing of the visual fields. 
19 
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Up to the age of 30 years, visual acuity (visus) remains normal and is 
generally easily corrected in all three types of the Usher syndrome. 
Nevertheless the patients' visual acuity gradually deteriorates and will have 
progressed to blindness in about 40% by the fifth decade, in about 60% by 
the sixth decade and in about 75% by the seventh decade34·52,53·5'1. 
At an early age (about 2 . 5 - 3 years) the electroretinogram (ERG) and 
electro-oculogram (EOG) can be subnormal, without the retina showing any 
signs of RP. As RP progresses, the ERG becomes non recordable and the 
EOG shows no lightrise. 
The age at onset and/or diagnosis of RP overlaps in all types of the Usher 
syndrome, although it is more consistent within sibships than between 
different sibships55. Ophthalmoscopic examination typically shows slowly 
progressive retinitis pigmentosa. It starts with granular accumulations of 
pigment and gives the appearance of bone corpuscles in the midperiphery of 
the fundus with extension towards the periphery. The visual fields slowly 
constrict and this is accompanied by decreasing visual acuity because of 
posterior pole involvement and of cataract formation53,55. Blindness is due to 
degeneration of both the cone and rod photoreceptor cells. Optic discs 
become waxy and there is narrowing of the arterioles. 
Associated symptoms 
Psychiatric abnormalities and mental retardation are sometimes associated 
with the Usher syndrome. Hallgren13 reported mental deficiency in 24% of 
the cases in his study. This association has not been confirmed in other 
series14,3''·46. In the early classification of Merin et al30 this group was referred 
to as type IV, but the existence of this separate type of Hallgren syndrome 
has not been confirmed. 
Various psychiatric disorders, such as a schizophrenia-like disorder, atypical 
psychosis and recurrent depression, have been associated with the Usher 
syndrome8,13·14·29. There are two theories for this: one theory is that it forms 
part of the syndrome and reflects a pleiotropic effect of the Usher gene. The 
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second theory is that the psychiatric dysfunction is caused by stress and is a 
reaction to the loss of two major sensory functions. 
Laboratory findings 
Blood and urine test results are normal, while EEG abnormalities have been 
found inconstantly14'56. Bazan et al56 reported decreased docosahexaenaoate 
and arachidonate in plasma phospholipid, but this has not been confirmed. 
Histopathologv 
Very few studies describe the histological findings in the inner ear. The bony 
cochlea is normal. Histological findings in types I, II and possibly III have 
shown degeneration of the organ of Corti, loss of cochlear neurons and 
degeneration of the spiral ganglia57'67. Atrophy of the stria vascularis was also 
found in most studies. 
A microtubular abnormality of sperm cells has been suggested by Hunter et 
al68, but there has been no conformation. 
Only Hunter et al68 reported the histopathological findings in the eye of an 
Usher patient. These were characterized by chorioretinal degeneration; all the 
retinal layers were present in the paracentral region, including remnant, 
shortened photoreceptors. Ultrastructurally, the inner segments were shorter 
than normal, the outer segment contained stacked discs, while connecting cilia 
linked the inner and outer segments. In the midperiphery, there were no 
photoreceptor outer segments or connecting cilia, but remnant inner segments 
were present. In the far periphery, there were no remnant photoreceptors. The 
pigment epithelial layer was directly apposed to the apical processes of 
Müller cells. 
In this overview of the Usher syndrome, all the most recent literature data 
have been included up to the end of August 1995, with the exception of the 
findings described in this thesis. This postgraduate project was started in 
Nijmegen in 1991. Our own findings are described in the chapters that follow 
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and have been intentionally omitted from this historical overview. For 
example, at the start of the project, no gene linkage results were available to 
support any of the clinical classifications for the Usher syndrome. A 
proportion of the gene linkage results for Usher types I and II were obtained 
during this study in Nijmegen. 
Aims of the study 
This study had the following aims: 
1. To promote gene linkage and gene isolation for the Usher syndrome type 
II 
2. To provide a detailed description of the clinical symptoms of Usher type 
2A on the basis of gene linkage results 
3. To determine whether the Usher syndrome gene is expressed in obligate 
carriers in the form of abnormal visual, auditory and vestibular responses 
4. To describe new histological findings in the inner ear of Usher syndrome 
patients. 
The study described in this thesis concentrated on the Usher syndrome type 
II, i.e. the group of patients with hearing impairment. This design was chosen 
because it was expected that a sufficient number of patients could be reached 
and communication with participants would not form too much of an 
obstacle. 
The study population 
All the patients known to have the Usher syndrome at the Ear, Nose and 
Throat Department (Prof. Dr С. Cremers) and Ophthalmology Department 
(Dr A. Pinckers) of the University Hospital Nijmegen (UHN) formed the 
starting point for this study. Owing to long-term ENT consultancy (by Prof. 
Dr С. Cremers) and Ophthalmology consultancy (by Drs. J. Cruysberg) from 
the UHN for deaf-blind patients at the nursing home 'Kalorama' in Beek-
Ubbergen, it was an obvious step to seek the co-operation of Kalorama 
22 
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(Drs. M. Benraad-van Rens). The Foundation for Deaf-Blind Patients (Mrs. 
A. Balder) was also willing to play a mediating role and enquire whether any 
of the members with the Usher syndrome would consider taking part in the 
ongoing study. In order to contact families with more than one affected 
person with the Usher syndrome type II, an appeal was made to the 
Interuniversity Ophthalmological Institute (Prof. Dr E. Bleeker-Wagemakers) 
in Amsterdam. 
Study methods 
After it had been agreed to make home visits, the patients and families were 
visited at home to obtain the necessary permission and enlist their co-
operation. The participants received an explanation about the aim of the study 
and gave their permission for us to obtain any relevant medical documents 
and data from elsewhere. In this way it was possible to limit the extent of the 
examination, while also having access to any relevant information, e.g. long-
term audiometrie data. Notes were made about developmental stages during 
childhood and about the medical history. Participants were also asked whether 
they knew of any consanguinity. 
Medical examination of the affected persons was aimed at the ear and eye. 
Audiological examination comprised otoscopy, tone audiometry, speech 
audiometry, brainstem audiometry and vestibular examination using a rotatory 
chair and electro-nystagmography. In incidental cases, stapedius reflex 
measurements were performed. 
Ophthalmological examination comprised fundoscopy, visual acuity testing, 
visual field measurement, electroretinography (ERG) and electro-oculography 
(EOG) in incidental cases. In this study, we gave particular preference to 
involving families with more than one affected person, because these families 
were considered to be more informative for gene linkage studies and clinical 
studies. For the purpose of making progress in the early stages of the study, 
families with only one affected person were included. 
23 
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The medical examination of the obligate carriers comprised: 
+ otoscopy, tone audiometry, speech audiometry, stapedius reflex 
measurements and brainstem audiometry 
+ ophthalmological examination, with fundoscopy, visual acuity testing, 
visual field measurement: electroretinography (ERG) and electro-
oculography (EOG). 
Gene linkage studies 
Since 1987, there has been co-operation between the ENT department of the 
UHN (Prof. Dr С. Cremers) and the Boys Town National Research Hospital, 
Omaha, Nebraska USA (Prof. Dr W. Kimberling) in the field of the branchio-
oto-renal syndrome. There was considerable need to draw in other researcher 
partners so that existing knowledge could be expanded with additional clinical 
data and blood samples from families with members affected by the Usher 
syndrome. This offered the opportunity to embark upon an affiliated Dutch 
project in Nijmegen. 
The double sensory handicap of this group of patients provided additional 
motivation to choose this study group. As part of the present study, blood 
samples were collected on pre-arranged dates from all the family members 
with two or more affected members as well as from all family members with 
one affected member and consanguinity. These were then flown directly to 
Boys Town for gene linkage, so that the gene could be linked more 
accurately and later isolated. 
Owing to the fact that family members without consanguinity and with one 
affected person had not yet been included in the gene linkage study in Boys 
Town, it was possible via the Anthropogenetic Institute (Dr F. Cremers) of 
the University of Nijmegen, to give a positive answer to a request to supply 
blood from isolated patients with the Usher type II syndrome so that it could 
be determined through them whether even more accurate gene linkage for 
Usher type 2A could be achieved. 
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The study results are presented in successive chapters. 
Chapter 2 describes the separate findings in the obligate carriers of Usher 
type 2A. This chapter also presents an article on the electro-oculogram in 
heterozygote carriers of the Usher syndrome (including type 2A), retinitis 
pigmentosa, neuronal ceroid lipofuscinosis, the Senior syndrome and 
choroideremia. 
Chapter 3 gives detailed audiological data and particular attention is paid to 
the long-term results. 
Chapter 4 presents the ophthalmological findings These include the results of 
colour-vision testing in patients with retinitis pigmentosa, some of whom had 
Usher type 2A. 
Chapter 5 reports the histological findings in the inner ear of one patient with 
Usher type I. 
Chapter 6 presents the results of the gene linkage studies performed in 
Omaha and in Nijmegen, some of the results were obtained in the present 
clinical study. 
Chapter 7 gives the final conclusions and general discussion. 
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The Usher syndrome type 2A 
ABSTRACT 
Ten obligate carriers of Usher syndrome type 2A from 5 different families 
with 2 affected persons all underwent audiologic, vestibular and 
ophthalmologic examinations. They had a sensorineural hearing loss which 
was in excess of that expected for their age at all of the frequencies (0.25 - 8 
kHz) tested, however, only a 10 dB (average) excess in hearing loss at 0.25 -
0.5 kHz proved to be significant. The speech discrimination scores obtained 
conformed with the hearing thresholds. Tympanometry, acoustic reflex and 
brainstem auditory-evoked potential findings were generally normal. Some 
vestibular abnormalities were found in a minority of the carrier sample, but 
not beyond the level of false positivity. Ophthalmologic findings were 
essentially normal, although in 5 carriers there was a subnormal electro-
oculogram (EOG). These findings are not sufficient specific for carrier 
detection. 
INTRODUCTION 
The Usher syndrome is an autosomal recessively inherited syndrome with 
congenital bilateral sensorineural deafness and retinitis pigmentosa (RP)1'2. 
This leads to progressive visual field loss (tunnel vision); posterior 
subcapsular cataracts also arise. RP can result in blindness through central 
visual acuity loss. The Usher syndrome is the most prevalent genetic cause of 
deafness and blindness3,4. At present 3 types can be distinguished on clinical 
grounds. Type I is characterized by RP and profound childhood deafness and 
an insensitive or hyposensitive vestibular labyrinth; type II is characterized by 
RP and a moderate sensorineural hearing loss and a sensitive labyrinth. Type 
III is like type II, but the sensorineural hearing loss is progressive. A rapid, 
easy and inexpensive test with a high sensitivity and specificity for the 
detection of the carrier state of the Usher syndrome is needed. Based on gene 
linkage studies, Usher syndrome type I is split up preliminary in type 1A that 
links to chromosome 14q325·6, type IB that links to chromosome 1 lql3.57 , 8 
and type 1С that links to chromosome lip 8 . Type II is split up into type 2A 
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linked on chromosome Iq32-q414 and a type 2B that is unlinked to lq32-
q419. The literature on this topic is scarce or contradictory. A review is given 
of the literature and our own results are presented. 
SUBJECTS AND METHODS 
Ten obligate carriers of the Usher syndrome type II underwent extensive 
otologic, audiologic, vestibular and ophthalmologic tests. The 5 families 
studied all counted two Usher patients. The diagnosis of the Usher syndrome 
was based on the medical history, otoscopie, audiologic, vestibular and 
ophthalmologic findings. Gene linkage studies of the affected and non-
affected family members showed linkage to chromosome I and therefore 
those families are classified showing type 2A Usher syndrome. 
Pure-tone audiograms were measured in a special sound-proof room 
according to the ISO 8253 (I989)10 standard, testing at 0.5, 1, 2, 4 and 8 kHz 
for air and bone conduction. All threshold testing used 5 dB intensity 
increments. The ISO 7029 method (1984)" was followed to calculate P50 
(50th percentile) threshold values for presbycusis for each patient individually 
at each frequency, in relation to his or her age and sex. This method is very 
similar to that reported by Robinson12. 
Monaural speech discrimination scores were obtained using the same set-up 
and standard Dutch phonetically balanced word lists consisting of ten 
monosyllables. Maximum speech discrimination scores (DmjJ were derived. 
Tympanograms and contralateral and ipsilateral acoustic middle-ear muscle 
reflexes were elicited and recorded. Brainstem auditory-evoked potentials 
(BAEPs) were obtained. The method has been previously reported in detail13. 
Eye movements were recorded with d.c. electronystagmography (ENG). 
Calibration of eye movement was obtained before each test. Saccades, smooth 
pursuit (SP), and optokinetic nystagmus (OKN) responses were tested; gaze 
positions were tested to see whether there was any gaze-evoked nystagmus13. 
Vestibular tests were conducted with the patient in the dark with the eyes 
open. Velocity step (VS) tests were performed with a Tönnies rotatory chair 
and the postrotatory nystagmus response were analysed as previously 
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reported14 using 90% confidence limits for the parameters initial velocity (V), 
time constant (T) and 'Gesamtamplitude' - cumulative eye displacement -
(δ)15 (and classified into the categories normoreflexia, hyporeflexia and 
hyperreflexia). The values of directional preponderance (DP) parameters were 
also calculated (similar to the side effect, see below) to assess directional 
asymmetry of the responses. DP values in excess of 25% indicate significant 
asymmetry15. For the caloric side effect (SE), we arbitrarily assumed a 
relative side difference, i.e. (difference/sum) 100%, in excess of 20% to 
indicate unilateral hypofunction. For the 95% confidence limits of the 
absolute response level, we took the values of 7°/s and 45°/s previously 
established16. All of the carriers underwent a routine ophthalmologic 
examination. In addition, their visual fields were evaluated with Goldmann 
perimetry, using test targets 1-1 - 1-4, III-4 and V-4, and they underwent 
electro-oculography (EOG) and electroretinography (ERG) examinations as 
previously reported17'18. 
Blood-samples from the patients and their family members as shown in the 
pedigrees were collected for gene linkage studies in Boys Town National 
Research Hospital. 
RESULTS 
Figure 1 shows the pedigrees. In 2 families (B and D), there was a 
consanguineous mating. Consanguinity was excluded within 5 generations in 
family A. No genealogie data were available on families С and E. Gene 
linkage studies performed in Boys Town National Research Hospital showed 
for all families by linkage to Iq32-q42 having Usher syndrome type 2A. 
Otoscopy was normal in all 10 carriers. None had in their medical history any 
hearing impairment, relevant ear disease, exposition to ototoxic drugs or noise 
trauma. Table 1 shows the audiometrie results and speech discrimination data 
of the 10 affected Usher cases. The hearing loss was symmetrical in all those 
affected and more marked at the higher frequencies. The pure tone average 
(PTA) at 0.5, 1 and 2 kHz varied from 30 to 93 dB. The maximum speech 
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discrimination score was 80% or better, except in Nos 5 and 6. All had 
normal tympanograms. All except Nos 5 and 6, showed normal acoustic 
reflexes and BAEP findings. In Nos 5 and 6 who had the most severe hearing 
loss (Table 1), wave V, in as far as it could be identified, showed increased 
(absolute) latency. Vestibular examination revealed normal caloric responses 
but abnormal rotatory responses (i.e. hyporeflexia or hyperreflexia). The 
results of the ophthalmologic tests are shown in Table 2. The ERG was non-
recordable. All the patients except for two had tunnel vision. 
Table 3 shows the results of tone audiometry and speech audiometry for the 
obligate carriers. The air-bone gap (ABG) values are included. The excess in 
hearing loss for the air conduction (AC) threshold, i.e. AC+, was calculated as 
AC+ = AC - P50 (see Methods). 
A 
Π 4 l <S Й2 ¿ f 
С 
6 5 
¿6 І 5 
«Sí 
13 О B 4 
17 ¿a 
Г : 
4 3 
H · affected male 
• unaffected male 
1Ш • obligate male carrier 
• affected female 
- unaffected female 
• obligate female carrier 
Figure 1. Pedigrees of families with Usher syndrome. 
The numbers are identification numbers. 
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Table 1. Pure tone and speech audiometry results in 10 Usher patients. 
dB Hearing Loss АС^олцо/ 
Patient Age Sex Ear 0 25 kHz 0 5 kHz 1 kHz 2 kHz 4 kHz 8 kHz PTA! D
m
„' 
No. (yr) 
Al 
A2 
B3 
B4 
C5 
C6 
D7 
D8 
E9 
ЕЮ 
48 
45 
56 
41 
36 
38 
27 
24 
25 
21 
F 
M 
M 
M 
F 
M 
M 
F 
F 
M 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
45, 
45, 
40, 
35, 
20, 
15, 
50, 
40, 
60, 
55, 
50, 
45, 
30, 
20, 
10, 
15, 
35, 
45, 
20, 
10, 
ι 60,,,^,, 
) 55,35^20) 
) 60,„„, 
) 55,s5HD) 
, ΙΟ,,ο.ο, 
) ^ " ( ] S + ]<¡) 
) °"l 6O+--20) 
) ->0(SO+0) 
) 3 0 ( 2 5 t 5 ) 
) 2 5 ( l 5 + 1 0 ) 
o5(SÛ+|5) 
^^(25+20) 
20 
^
u(20<0) 
-^-Vo+is) 
-^(30+0) 
" " ( 70+'20) 
"5( · , 7 0 + 15) 
"^(70 + 10) 
•"(4S+10) 
5<W„ 
55(55»ο) 
60(40+10) 
θ5(60*5) 
- " ( H + 0 ) 
^^(25*15) 
"0(70*10) 
"^(6W0) 
"^(бО'Ч) 
' 5 ( b S + | 0 ) 
"ЦоО+0) 
70(6„„ 
70,6w„ 
' 0 * ( 70' 11) 
"->(
 6 0 + 25) 
1 15( 7(1+ 4*.) 
1 0 5 ( 70+ js) 
6 5 ( 6 1 . 0 ) 
65(b0+<¡) 
60 ( 6 O , O ) 
60(6o*o) 
" * ( 6 0 * ΐ ) 
6 0 ( 6 0 + 0 ) 
->"(S0 + O) 
50(^0+o) 
"^(•M+OS) 
9 0 
7 υ ( 60 + 10) 
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°"( is+2S) 
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1 0 b (
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120 ( 6 0 v 60j 
° ^ ( 60* 1) 
' -\бО+И) 
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6 0 ( (.о* 0) 
6 5 ( 6 0 , , , 
> ι o o ( . 4 0 _ 6 0 ) 
> i o o ( 4 ( H 6 0 ) 
'-V40+-O5) 
' ^ ( 40* ]1) 
7 0 
, υ ( 40+ 30) 
° 5 ( 40*-4S) 
> 1 0 0 , .
№
 60, 
> i o o , ,
№ 6 0 ) 
>ioo,
 40.,60) 
>ioo,
 40. M | 
7 0 , 4 0 + 3 0 ) 
' " (-,40* 30) 
" 0 ( > 4 0 + < 5 o , 
75,^40r-35) 
7 0 
' 5 , 40+ JS) 
"^(>40+ 2S) 
6 5
с > 4 0 + ^ 2 5 ) 
68 
60 
63 
67 
38 
30 
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45 
90 
78 
93 
87 
55 
50 
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48 
60 
58 
38 
38 
80 
95 
100 
95 
95 
95 
95 
95 
75 
75 
70 
75 
90 
95 
95 
95 
95 
95 
95 
95 
Abbreviations. -, Not measured, >, Outside the range of the audiometer, 'Hearing loss, Air Conduction 
threshold (Bone Conduction threshold + Air-Bone Gap), 2Pure tone average of 0 5, 1,2 
kHz (PTA), 'Maximum speech discrimination (D
m a
J. 
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ССР 
IO 
OD TV" 
OS T V 
OD TV" 
OS TV" 
OD 0 67 
OS 0 50 
OD 1 0 
OS 1 0 
ODO 
OSO 
ODO 
OSO 
ODO 
OSO 
ODO 
OSO 
Table 2 Results of ophthalmologic tests in 10 Usher patients 
Patient Age Sex Vision' Fundus2 Media1 Goldmann4 EOG' ERG ERG 
No (yr) -CF" -RF6 
Al 48 F ODS+0 50, C-2 0, 165°/02 RP CCP OD TV 5° OD 1 08 OD 0 OD 0 
OS S+0 50, C-2 0, 5° / 0 08 OS TV 5° OS 1 04 OS 0 OS 0 
A2 45 M OD S-2 0, C-2 0, 50° / 0 3 RP CCP OD TV 10° OD 1 22 OD 0 OD 0 
OS S-20, C-I 25, 180°/02 OS TV 5° OS I 38 OSO OSO 
B3 56 M ODS-7 5 / 0 2 5 " RP 
OS S-7 0, C-I 25, 165°/0 4" 
B4 41 M ODS-6 5, C-I 0, 10°/1 0" RP 
OSS-6 25, C-I 25, 175°/ I 0" 
C5 36 F ODS-1 0, C-0 50, 180°/05 RP CPP OD TV 20° OD 1 11 OD 0 OD 0 
OS S+0 5, C-0 50, 180°/05 OS TV 20° OS 1 0 OS 0 OS 0 
C6 38 M OD S C / 0 8 RP CC OD TV 10° OD 0 62 OD 0 OD 0 
OS SC / 0 8 OS TV 10° OS 0 60 OS 0 OS 0 
D7 27 M OD S-0 50 / 0 5 RP CCP OD TV 20° OD I 0 OD 0 OD 0 
O S S - 1 0 / 0 4 OD TV 20° OS 1 0 OS 0 OS 0 
D8 24 F OD S-0 50, C-0 50, 180°/05 RP CPP OD TV 25° ODIO OD 0 OD 0 
OS S-0 50, C-0 50, 180° / 0 3 OD TV 25° OS 0 88 OS 0 OS 0 
E9 25 F OD SC / I 0 RP N PRS OD 0 86 OD 0 OD 0 
OS S C / 0 8 OS 112 OSO OSO 
E10 21 M O D S C / 1 0 RP N PRS OD 1 10 OD 0 OD 0 
OS SC / 0 8 OS 1 08 OS 0 OS 0 
Abbreviations 'Examined elsewhere, 'Vision - Spherical (S), Cylindrical (С), Sine Correction (SC) 
2Fundus Retinitis Pigmentosa (RP), 'Media Cataracta Corticalis Posterior (CCP), 
Normal (N), Increased (lens) Opacity (IO), Cataracta Polaris Postenor (CPP), Cataracta 
Capsulaos (CC), 4Goldmann perimetry (V-4) - Tunnel Vision (TV), Partial Ring Scotoma 
(PRS), 5Elcctro Oculography (EOG) - lower limit normal (5% limit) Lp/Dt (Arden) ratio 
1 80, 'Electro-Retinography (ERG) - Cone Function (CF) lower limit normal b wave 
100 micro Volt, Rod Function (RF) lower limit normal b-wave 150 micro Volt (absolute 
limits) 
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Table 3. Pure tone and speech audiometry results in 10 obligate carriers. 
dB Hearing Loss: АС,в
С
 .
 W0)' 
Carrier Age Sex Ear 0.25 kHz 0.5 kHz 1 kHz 2 kHz 4 kHz 8 kHz PTA2 D
m 
No. (yr) 
Al 14 F R 15,, 
L 15,., 
5,i.0> 
'О(очо) 
5(0-5) 
^ i i . n , 
"(04)) 
5(1+0) 1^(10*0' 
100 
100 
A2 72 F 20,., 
20,., 
20,,,.,, '^(10*0) 
ΙΟ,ο,,ο) 
25 ( 2,. 0 ) 35 ( M M „ 30,,,., S) 18 100 
15^, 0 , 2 5 , w o , 25,2 0.„ 12 100 
B3 29 F 
B4 31 
R 
L 
R 
L 
15,, 
25,, 
15,, 
20, 
20, n 
I5,i 
5,0.1) 
20,ц., , '^(io«o) 
^ ( 1 1 + 1) -*"1 >(0·1) 
10,,,., 
5,0+M J (0*5) 
5(0*5) 
5,5.0) 
5(0.5) 
IO,,.,, 
•0,5.5, 
5(0.5) 
10 
10 
10 
100 
100 
100 
100 
C5 62 F R 
L 
20,. 
20, 
J,5.0) 
5(0.5) 
U ( 0 .0) 
0(0.0) 
5(5.0) 
"ííi+n» 
5,5.0) 
"(0*0, 
'5( |5^(, 100 
100 
C6 65 M 20,. 
20, 
го,,,.,, 
20, 
15,, ι.0) 
'5,1. ιοί 
•^(lO-O) 
J^(IO.O) 
50 ( 4i.S ) 90,.4 0.. ; 22 95 
95 
D7 54 M 40,, 
35,, 
SO,«.,, 
20,,,.,, 
5(0.5) 
10,„ 
10„ 
15,1 
35,25.„ 
35,, '0,.ή0..3, 15 
95 
95 
D8 53 F 10,, 
10,, 
10, (0-10) 
5(0*5) 
5(0.5) 
5,0-5) 
J(5»0) 
IO,,.,, 20„ 
IO,,.,, 100 
95 
E9 59 M R 
L 
10,. 
15, 2 0 , „ . „ 
20 
^
υ (20+0] 
J " n o . i [ 
4^,40+0) 
35,э5+о) 
50,4 
50„ 
25,11. ,o, 28 100 
95 
ЕЮ 49 F 10,. 
20, 
-*ÍS4)Í 
io,. io,. 100 
100 
Abbreviations: -, Not measured; >, Outside the range of the audiometer; 'Hearing loss: Air Conduction 
threshold (Bone Conduction threshold + Air-Bone Gap); 2Pure tone average of 0.5, 1, 2 
kHz (PTA); 'Maximum speech discrimination (Dm„). 
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Table 4 Excess in hearing loss for the air conduction threshold (AC*) in 
relation to the Ρ50 threshold values for presbyacusis for each 
carrier individually at each frequency for his or her age and sex 
dB Hearing Loss AC* = AC - P50 
Carrier Age Sex Ear 0 25 kHz 0 5 kHz 1 kHz 2 kHz 4 kHz 8 kHz 
No (yr) 
Al 14 F 
A2 72 
ВЗ 29 
B4 31 
С5 62 
С6 65 M 
D7 54 M 
D8 53 
Е9 59 M 
ЕЮ 49 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
+ 15 
+ 15 
+ 11 
+ 11 
+ 14 
+24 
+ 14 
+ 19 
+ 14 
+ 14 
+ 13 
+ 13 
+36 
+31 
+6 
+6 
+4 
+9 
+7 
+ 17 
+5 
+ 10 
+ 10 
+5 
+ 19 
+ 19 
+ 19 
+ 14 
-2 
-2 
+ 12 
+ 12 
+25 
+ 15 
+5 
0 
+ 19 
+ 14 
+ 16 
+ 1 
+5 
+5 
-1 
-1 
+4 
+9 
+4 
+9 
-8 
-8 
+6 
+6 
-1 
+4 
0 
0 
+ 13 
+23 
+ 1 
+ 1 
0 
+5 
+8 
-2 
+4 
-1 
+3 
+3 
-7 
-12 
+ 14 
+14 
0 
+5 
-3 
+2 
+28 
+23 
+4 
-1 
+ 10 
+5 
+ 10 
0 
+3 
+3 
+3 
+3 
-13 
-18 
+ 14 
+4 
+ 14 
+ 14 
-12 
+8 
+23 
+23 
+ 1 
+ 1 
+ 10 
+ 10 
-11 
-16 
+8 
+8 
+ 17 
+2 
-15 
-25 
+41 
+51 
+31 
+41 
-9 
+36 
-12 
-2 
0 
-5 
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Table 4 presents the AC+ values obtained Probit analyses (not shown) 
demonstrated that the AC+ values (as well as the ABG values) had 
approximately normal distributions at all of the frequencies. 
The statistics for AC+ were calculated for each ear and frequency (Table 5). 
Table 5 shows the SEM (standard error of the mean) values which were used 
to test (Student's t test) whether the mean values differed significantly from 
zero (P < 0 05). This was found to be the case at 0.25 and 0.5 kHz for both 
ears. According to Student's t test, the mean AC+ value at 0.25 kHz was 
significantly higher than that at 1 kHz in the right ear and those at 1, 2 and 4 
kHz in the left ear; in the right ear, also the AC+ value at 0.5 kHz was 
significantly higher than that at 1 kHz 
Table 5 AC+ values (dB HL) with their statistics Student's t test was 
applied to identify mean values, which were significantly 
different from zero 
Ear 
R 
L 
η 
mean 
SD 
SEM 
t 
η 
mean 
SD 
SEM 
t 
0 25 kHz 
10 
13.4 
88 
28 
4.8 
10 
15.9 
74 
23 
6.8 
0 5 kHz 
10 
12.8 
83 
26 
4.9 
10 
8.8 
73 
23 
3.8 
1 kHz 
10 
23 
55 
1 8 
1 3 
10 
48 
82 
26 
1 9 
2 kHz 
10 
5 1 
99 
3 1 
1 6 
10 
36 
95 
30 
1 2 
4 kHz 
10 
53 
11 4 
36 
1 5 
10 
43 
105 
33 
1 3 
8 kHz 
10 
60 
192 
6 1 
1 0 
10 
100 
25 1 
79 
1 3 
Significant values in bold italic print 
43 
Chapter 2A 
Table 6. Mean values (dB HL) for both ears for AC* and ABG and 
their difference 
0 25 kHz 0 5 kHz 1 kHz 2 kHz 4 kHz 8 kHz 
A C 15 11' A A 5 8 
ABG &> 6 4 3 6 5 
AC* - ABG 9? 5 0 1 - 1 3 
Abbreviations *, Significant difference between AC' and ABG (Student's t test, Ρ < 0 05), 
Bold italic print indicates values significantly different from zero 
Table 3 shows that there was some ABG with a mean value of about 5 dB 
(Table 6). After calculating SD and SEM values for the ABG (not shown), it 
was found that the mean ABG was significantly different from zero at all 
frequencies (Student's t test, Ρ < 0.05). It appeared that AC+ differed 
significantly from the ABG only at 0.5 kHz (Table 6). Assuming that the 
statistics for the ABG at 0.25 kHz (measurements were not available) were 
similar to those found at 0.5 kHz (not shown), it can be concluded from the 
present measurements and analyses that the observation of a significant 
(excess in) sensorineural hearing loss (with reference to the P50 of 
presbycusis, see Methods) was present only at 0.25 and 0.5 kHz. This (excess 
in) sensorineural hearing loss, i.e. AC+ corrected for the apparent conductive 
loss, was about 5-10 dB on average (Table 6). 
Analysis of the regression of AC+ at 0.25 or 0.5 kHz on age (not shown) did 
not reveal any significant correlation. 
All carriers showed normal tympanograms. Acoustic reflexes were normal in 
all except No 7; reflex thresholds were found at levels of between 80 and 100 
dB and there was no pathologic reflex decay, i.e. a reflex decline of more 
than 50% within 10 s. Carrier No 7 showed bilateral threshold elevation at 
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0.5 and 1 kHz. All the carriers showed normal BAEP results. 
Table 7 presents the vestibular findings. None of the carriers showed 
spontaneous or gaze-evoked nystagmus or any abnormal Saccades, SP or 
OKN responses. Caloric abnormalities were found in 2 subjects (Nos 1 and 
8), i.e. significantly high response levels. This feature was linked to the 
finding of hyperreflexia in the VS test. Abnormal VS responses were found 
in 6 of the carriers, i.e. hyperreflexia in cases 1, 3, 5, 8 and 9 and 
hyporeflexia in case 6. None of the DP values were significant. 
Vestibular complaints were not mentioned by any of the carriers before 
examination. Carrier No 5, before being informed about the finding of hyper­
reflexia, mentioned her susceptibility to motion sickness. Carrier No 1 also 
showing hyperreflexia complained later about her dizziness, nausea and 
vomiting after the vestibular examination. Carrier No 6 showed hyporeflexia 
of the VS response and was a professional marine at sea. 
The ophthalmologic test results of the 10 obligate carriers are presented in 
Table 8. In 5 of the carriers (Nos 2, 5, 6, 9 and 10) the EOG was subnormal; 
one of them was also found to have an abnormal ERG (No 6). 
DISCUSSION 
The present results indicate that the carriers had an AC threshold which was 
in excess ofthat expected for their age (AC+) by about 10 dB at 0.25-0.5 kHz 
(Table 6). As they appeared to have about 5 dB conductive hearing loss, 
which we have no plausible explanation for other than the possibility of 
systematic error in the measurements, presumably bias introduced by 
avoidance of threshold values for bone conduction that are apparently higher 
than these for air conduction, the apparent sensorineural hearing loss at those 
frequencies had to be corrected for the ABG present (i.e. AC+ - ABG, see 
Table 6). The latter value was not equivalent to ВС, the bone conduction 
threshold in Table 3. If we had corrected the ВС values for (sex-related) 
presbycusis in a similar way to that done for AC following the ISO 7029 
procedure, we might have found similar values. However, as no such 
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procedure has been defined for ВС, there was no alternative. We assumed 
that the ABG was not age-dependent, which indeed appeared to be the case 
(the regression analyses are not shown). All of the carriers showed normal 
BAEP and tympanometric results. Acoustic reflexes were generally normal. 
The significant sensorineural hearing loss, therefore, can be regarded as 
cochlear in origin. Kimberling et al4,19 also performed BAEP, tympanometric 
and acoustic reflex examinations, but did not report in detail any of the 
results obtained. 
Table 7. Clinical and vestibulo-ocular data on the carriers 
Carrier Age 
No. 
Al 
A2 
B3 
B4 
CS 
C6 
D7 
D8 
E9 
ЕЮ 
(yrs) 
14 
72 
29 
31 
62 
65 
54 
53 
59 
49 
Sex 
F 
F 
F 
F 
F 
M 
M 
F 
M 
F 
VS 
R nystagmus 
V.T.G 
40, plateau 
49, 12, 588 
85, 15, 1275 
44, 16, 704 
71, 28, 1988 
23, 14, 322 
50, 16, 800 
68, 12, 816 
56, 14, 784 
39, 20, 780 
response 
L nystagmus 
V,T,G 
46, 32, 
52, 13, 
72, 14, 
37, 18, 
68, 24, 
15, 14, 
48, 23, 
58, 15, 
66, 18, 
39, 19, 
1472 
676 
1008 
666 
1632 
210 
1104 
870 
1186 
741 
Calories 
LC.RC' 
50, 50 
18,21 
13, 14 
14, 15 
41, 52 
10, 9 
20, 17 
16, 21 
36, 32 
10, 14 
Remarks 
dizziness, nausea, 
vomiting afterwards 
susceptible to motion sickness 
often at sea 
Abbreviations significant values in bold italic print; 'Left cold, Right cold 
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Chapter 2A 
The present results and those reported by others indicate that sensorineural 
hearing loss can be observed among type II carriers. However, it can be 
distinguished from presbycusis only with some difficulty, for example by 
applying the present methods. We have no explanation for the present 
observation that the sensorineural hearing loss manifested itself predominantly 
at the lower frequencies in the carriers, whereas the affected persons showed 
their predominant hearing loss at the higher frequencies. The hearing loss of 
the carriers in this study may represent partial expression of the (more severe) 
hearing loss shown by the affected persons at the lower frequencies. In view 
of the above-mentioned normal BAEP findings in the affected persons, one 
would expect to find normal BAEP examinations only in the obligate carriers, 
which turned out to be the case. The same was true for the tympanometric 
and acoustic reflex examinations. 
In the literature, very few articles are available on possible clinical 
abnormalities in carriers of the Usher syndrome20"22. In other studies, one 
single family was described23'28 or the carriers were only mentioned 
indirectly4·19·29'30. 
The lack of clinical data and the lack of gene linkage results on affected 
persons means that it is not always clear which type of the Usher syndrome 
was studied c.q. or in which type of carrier the abnormalities were diagnosed 
(Table 9). Therefore, no direct comparison can be made between our results 
in obligate type 2A carriers and previously reported results. 
Only three earlier studies present the audiograms of obligate (O) c.q. possible 
carriers (P)23,24,27. Two additional studies mention either the mean hearing 
losses for the various frequencies20 or the mean hearing loss is presented in 
figures28. An overview of the hearing losses in the various studies is given in 
Table 10. No technical data on audiometry were reported in the majority of 
studies, therefore we cannot make any meaningful direct comparisons with 
our findings. 
We have already mentioned our reservations about some of the vestibular 
findings, for example, the responses which showed hyporeflexia (low V and 
G values) in carrier No 6, who might have developed vestibulo-ocular reflex 
(VOR) suppression in response to his professional activities. 
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Table 9. Overview of clinical studies on carriers in the literature. 
Author Type Usher No. + type Audiometry Vestibular Fundusscopy Perimetry ERG/DA EOG 
syndrome' of carriers3 test 
Hallgren" 
Kloepfer20 
Goode" 
de Haas21 
McLeod2" 
Holland" 
Davenport23 
Sondheimer22 
I 
I 
Il/III 
I + Il/III 
Il/III 
I + Il/III 
II 
7 
Karjalainen2627 III 
Grondahl2' 
Kimberling" 
Kimberling4 
Tamayo10 
I + II + III 
I + II 
I + 11 
7 
9 0 
4 0 
28 0 
22 Ρ 
2 0 
3 Ρ 
14 О 
5 Ρ 
8 О 
1 Ρ 
8 О 
2 Ρ 
2 О 
14 О 
1 О 
6 Ρ 
35 О 
23 О 
20 О 
8 О 
+ (4) 
ERG 
DA 
ERG+DA + 
ERG + 
DA 
DA 
ERG 
ERG 
ERG 
Abbreviations. +, Mentioned in methods, -, Not performed; ?, Unclear; 'Type Usher syndrome, - author's 
classification is shown in bold italics 2Camer type Obligate (O), Possible (P) carrier. 
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The Usher syndrome type 2A 
Hyperreflexia was found in 4 other carriers, of whom at least 2 (Nos 1 and 5) 
were suspected of being susceptible to motion sickness. If we exclude these 2 
carriers and the above-mentioned carrier No 6 from the present evaluation, 
hyperreflexia occurred in 3 cases out of the 7, which may have been due to 
false positivity15. It is possible that in carrier Nos 1 and 5, motion sickness 
was secondary to their abnormal VOR behavior. Be this as it may, for the 
moment it seems that the odds are against the type 2A carriers having 
specific vestibular abnormalities. 
In the literature, 10 obligate carriers of a presumed type II Usher syndrome 
were tested by other authors and only 2 of them were found to have reduced 
caloric responses. If we include the report by Karjalainen et al26 the score for 
hypo-excitability in type II/III carriers is 2 out of 12 and, including the 
present report, it is 2 out of 22 carriers. This can certainly be reconciliated 
with false positivity at a presumed level of significance of 5%. 
Although several authors mentioned employing SP19, and OKN tests19,28, no 
results pertaining to carriers were mentioned in their reports. We could not 
find any reports about rotatory tests on carriers. 
Our ophthalmologic investigations did not show any RP-specific fundus 
changes in the carriers; the media were normal for their age. Sondheimer et 
al22 did not find any fundus abnormalities either, in 14 obligate carriers (type 
unknown). Fundus and media abnormalities in carriers were reported by 
Kloepfer et al20 in 4 out of the 13 carriers (type unknown); they displayed a 
fundus picture typical of RP. During re-evaluation, 3 out of the 4 did not 
have RP, but gyrate atrophy-like fundus abnormalities, with abnormal ERG; 
the fourth did not have any fundus abnormalities25. These gyrate atrophy-like 
findings were later criticized by Sondheimer et al22. 
Conflicting results have been published in the literature on dark adaptation 
(DA) measurements21,22'29. In view of these findings and the fact that DA 
measurement is a subjective method, we chose objective test methods: EOG 
and ERG. Table 8 shows that the EOG and ERG results of some of the 
carriers were abnormal: 5 out of the 10 carriers had an EOG value of below 
the 5% lower confidence limit; 1 carrier also had an abnormal ERG result. 
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The literature also mentioned abnormal EOG and ERG results in carriers. The 
two parents (type II) examined by Davenport et al23 underwent general 
ophthalmologic tests, fundoscopy, perimetry and ERG tests and no 
abnormalities were found. One of the two carriers displayed subnormal EOG 
values. 
Tamayo30 found subnormal ERG values in 2 out of the 8 obligate carriers 
(type unknown). Hallgren31 did not find any abnormal ERG values in 4 
obligate carriers type I. 
Summarizing, no clear ophthalmologic abnormalities were found in carriers in 
this study, which supports the lack of abnormalities reported in carriers in the 
literature. Although EOG and ERG abnormalities were found, these methods 
do not appear to be sufficient sensitive and specific for the identification of 
heterozygotes. 
The fact that the affected persons were found to have vestibular abnormalities 
(hyporeflexia or hyperreflexia) might suggest the possibility that the obligate 
carriers also had (some) similar symptoms. As shown above, similar findings 
(i.e. hyporeflexia or hyperreflexia) were indeed encountered in the present 
study, but not beyond the level of false positivity. It seems justified to 
attribute the abnormal rotatory responses in the affected persons to functional 
impairment of the afferent visual system, caused by abnormalities in the 
peripheral retina. These features were generally lacking in the obligate 
carriers. 
The results of our study on 10 obligate Usher type 2A syndrome carriers and 
the review of the literature, indicate that it is not (yet) possible to identify 
carriers using extensive audiovestibular and ophthalmologic tests. 
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The electrooculogram in heterozygote carriers 
ABSTRACT 
Electrooculographic studies were performed in 77 carriers of tapetoretinal 
dystrophies: Usher syndrome (20), retinitis pigmentosa (32), neuronal ceroid 
lipofuscinosis (6), Senior syndrome (2), and choroideremia (17). The carriers 
were matched for sex and age with normal controls. 
In carriers of Usher syndrome the EOG Lp/Dt ratio was significantly lowered 
with 30% of the recordings having a subnormal value. There was a trend in 
carriers of retinitis pigmentosa to a subnormal EOG. In contrast to previous 
studies there was no decrease in the EOG Lp/Dt ratio in carriers of neuronal 
ceroid lipofuscinosis. Two carriers of Senior's syndrome had a normal EOG. 
Carriers of choroideremia did not differ significantly from normal controls; 
however, the Lp/Dt ratio decreased with increasing age. 
An abnormal EOG may be indicative of the carrier state in relatives of 
patients with tapetoretinal dystrophies. 
INTRODUCTION 
The tapetoretinal dystrophies are a heterogeneous group of disorders1. The 
primary metabolic defect lies in the retinal pigment epithelial layer, the 
photoreceptor cell layer, the bipolar/Müller cell layer, or in the ganglion cell 
layer2. Usher type I is characterized by retinitis pigmentosa (RP), complete 
deafness or profound hearing loss and an insensitive or hyposensitive 
(vestibular) labyrinth. In Usher type II, RP and hearing loss are present while 
the labyrinth remains sensitive. In Senior's syndrome there is a combination 
of nephronophthisis or cystic medullary kidney disease and signs of RP. In 
neuronal ceroid lipofuscinosis (NCL) the clinical diagnosis is confirmed by 
the electron microscopic demonstration of curvilinear (Jansky-Bielschowsky 
type) or fingerprint profiles (Spielmeyer-Vogt type) in lymphocytes or other 
body tissues. The diagnosis of choroideremia is based on the 
ophthalmoscopic findings and an X-linked recessive mode of inheritance. 
The inheritance pattern in many of the tapetoretinal dystrophies is a recessive 
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one. Heterozygotes or gene carriers may present with minor signs of retinal 
dysfunction. 
With the exception of the dystrophies which originate in the ganglion cell 
layer, the retinal functions in the end stage of the different types of 
tapetoretinal dystrophies are similar: the electroretinogram (ERG) is 
unrecordable, while the electrooculogram (EOG) becomes flat. In early stages 
of the disease processes the results of ERG- and EOG recordings depend on 
the primary site of the disease. There is a limited number of papers dealing 
with the EOG in carriers of tapetoretinal dystrophies. We present the results 
of EOG studies in carriers of a number of retinal dystrophies. 
MATERIALS AND METHODS 
We selected 77 heterozygotes/carriers of tapetoretinal dystrophies: retinitis 
pigmentosa (32), Usher syndrome (20), Senior's syndrome (2), neuronal 
ceroid lipofuscinosis (6), and choroideremia (17). The carriers were the 
parents or the children of homozygotes diagnosed as autosomal recessive 
cases, and heterozygote females in X-linked recessive cases. 
All patients underwent complete ophthalmological examination, including 
measurement of best-corrected visual acuity, slit-lamp examination, 
ophthalmoscopy, visual field examination, ERG and EOG. The ERG and 
EOG-recording procedures have been previously described3. The Darktrough 
(Dt) is the mean of the measurements at the 6th, 8th, 10th and 12th min. The 
Lightpeak (Lp) is the mean of the four maximum values during light 
adaptation. The EOG was considered subnormal when the Lp/Dt ratio (Arden 
ratio) was lower than 1.80 (95th percentile in our laboratory). 
Patients were matched for sex and age with normal controls. The Lp/Dt ratio 
of the right eye was calculated and the different groups of carriers were 
compared with controls. The Student t test was used with a one-sided 
significance level. 
58 
The electrooculogram in heterozygote earners 
RESULTS 
The Lp/Dt ratio for carriers of tapetoretinal dystrophies and of normal 
controls of the same sex and age are presented in Table 1. Also listed are the 
percentages of abnormal values for the Lp/Dt ratio (< 1.80) and the mean age 
of the patients. Table 2 presents the results of comparison between carriers 
and controls. 
Compared with normal controls, the Arden ratio was significantly decreased 
in carriers of the Usher syndrome (p<0.0005), more so in Usher type II than 
in Usher type I. In 30% of the carriers abnormal values could be established. 
It was noticed that within a given family the fundus picture was very similar. 
However, the inter-familial variation in both the Usher type I and Usher type 
II families was considerable: the fundus picture varied from "retinitis 
pigmentosa sine pigmento" to a typical RP pattern. 
In carriers of X-linked RP a significant difference from normal controls in 
Arden ratio could also be established (p<0.05). The difference between 
autosomal recessive RP and normals was not significant. In 34% of all 
patients with RP the Lp/Dt ratio was lower than 1.80. 
No significant decrease in Lp/Dt ratio could be established in carriers of NCL 
or in carriers of choroideremia. The percentages of abnormal values were 17 
and 24 respectively. In carriers of choroideremia the Lp/Dt ratio decreased 
with increasing age (Figure 1). The Lp/Dt ratio in the two carriers of the 
Senior syndrome were 1.98 and 2.63 respectively. 
DISCUSSION 
Electrooculography is a non-invasive examination method that does not 
impose a heavy burden on the patient. The interpretation of the clinical 
significance of the EOG results is not easy because of considerable intra-
individual variations4'5. The interindividual variations are even greater6. 
Notwithstanding these difficulties, a statistical evaluation of the EOG in well-
defined groups of patients sometimes yields surprising results7"9. 
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Table 1 The EOG in carriers of tapetoretinal dystrophies and in normal 
controls of the same sex and age (n=77) 
Group N Mean age EOG Lp/Dt ratio 
mean SD min max %abn 
Usher I + II 
normal 
Usher I 
normal 
Usher II 
normal 
"RP" 
normal 
XL-RP 
normal 
AR-RP 
normal 
NCL 
normal 
Senior 
normal 
Choroideremia 
normal 
20 
20 
10 
10 
10 
10 
32 
32 
10 
10 
22 
22 
6 
6 
2 
2 
17 
17 
52 9 
51 9 
57 4 
57 4 
48 4 
46 4 
39 8 
37 6 
32 6 
32 2 
42 5 
40 1 
34 2 
34 2 
50 5 
48 5 
29 0 
28 4 
1 86 
2 22 
1 88 
2 17 
1 83 
2 28 
2 09 
2 38 
1 88 
231 
2 19 
241 
2 17 
2 38 
231 
2 11 
2 27 
2 35 
0 25 
0 33 
0 27 
0 40 
0 22 
021 
051 
0 43 
0 57 
0 37 
0 45 
0 45 
0 30 
0 64 
. 
-
061 
0 37 
1 33 
1 63 
1 33 
1 63 
1 47 
1 87 
1 14 
1 69 
1 14 
1 86 
1 67 
1 69 
1 76 
1 93 
1 98 
2 00 
1 25 
1 95 
2 24 
2 78 
2 24 
2 78 
2 18 
2 56 
3 50 
3 33 
3 00 
3 04 
3 50 
3 33 
2 54 
3 74 
2 63 
2 22 
3 20 
3 50 
30 
10 
30 
20 
30 
0 
34 
6 
50 
0 
27 
9 
17 
0 
0 
0 
24 
0 
Abbreviations Autosomal recessive retinitis pigmentosa (AR-RP), Neuronal ceroid 
lipofuscinosis (NCL), Autosomal recessive and X-lmked recessive retinitis 
pigmentosa ("RP"), X-hnked recessive retinitis pigmentosa (XL-RP), 
percentage of abnormal values (Lp/Dt ratio < 1 80) (%abn) 
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Figure J. EOG/LpDt ratio of the right eye, plotted against age, in 
choroideremia (n=17) and normal controls (n=17). 
A search of the literature yielded three studies dealing with the results of 
EOG examination in carriers of the Usher syndrome10"12. The EOG recording 
techniques were identical with those described by Arden et al, setting the 
lower limit of the Lp/Dt ratio at 185%13. In about two-thirds of carriers the 
Lp/Dt was lower than 185%. Although the different authors did not subdivide 
patients according to Usher type, and did not make statistical calculations, it 
was clear that the EOG in carriers of the Usher syndrome is subnormal. The 
present study shows that the EOG Lp/Dt ratio in Usher carriers is 
significantly lower than in normal controls (p<0.0005), carriers of Usher type 
II group showing more deviation from normals (p<0.0005) than those of 
Usher type I (p<0.05). Especially in non-affected sibs of Usher type II, a 
subnormal EOG might indicate a carrier state. A subnormal Lp/Dt ratio was 
present in 30% of the carriers. 
Carriers of retinitis pigmentosa showed a trend towards a subnormal Arden 
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ratio (p<0.025). In the subgroup of autosomal recessive RP, no significant 
difference from normal controls could be established (Table 2). 
However, the difference between normals and carriers of X-linked recessive 
RP was significant (p<0.05). 
In 1916, Leber introduced the term tapetoretinal degeneration2. One of the 
subtypes in his classification was the amaurosis caused by the disease we 
know today as neuronal ceroid lipofuscinosis14. 
NCL has to be differentiated from Tay-Sachs disease which primarily 
involves the ganglion cell layer, and also from retinitis pigmentosa with 
primary involvement of the receptor cell layer2. NCL is inherited as an 
autosomal recessive trait. In its early stages the disease is characterized by a 
Table 2 Carriers with tapetoretinal dystrophies (n=77) compared with 
normal controls (Student t test with one-sided significance level) 
Usher I + II - normal 
Usher I - normal 
Usher II - normal 
"RP" - normal 
XL-RP - normal 
AR-RP - normal 
NCL - normal 
Choroideremia - normal 
Abbreviations Autosomal 
3.93 
1 91 
4 79 
201 
2 00 
1 62 
0 74 
0 93 
recessive retinitis pigrr 
< 0 0005 
< 0 05 
< 0 0005 
< 0 025 
< 0 05 
< 0 10 
< 0 25 
< 0 20 
lentosa (AR-RP) 
lipofuscinosis (NCL), Autosomal recessive and X-Iinked recessive retinitis 
pigmentosa ("RP"), X-linked recessive retinitis pigmentosa (XL-RP) 
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diminished ERG cone b-wave and a normal EOG. This is suggestive of a 
process which starts at the bipolar/Müller cell layer15. 
Later on, the disease spreads to the receptor cell layer and from the posterior 
pole (Batten-Mayou type) to the retinal periphery (Spielmeyer-Vogt type). 
Consequently the ERG becomes extinguished and the EOG flat16. 
Ultrastructural studies in both the Jansky-Bielschowsky and the Spielmeyer-
Vogt type of NCL are consistent with the electrophysiological findings17,18. In 
this study we report on six NCL carriers with normal EOG (one eye with 
Lp/Dt<1.80). This data has been published earlier15. Other investigators have 
reported a significantly lowered EOG lightpeak (p<0.05) and a reduced ERG 
scotopic b-wave amplitude in 19 obligate NCL carriers19. The authors did not 
attempt to explain why the EOG is normal early in homozygotes, but lowered 
in heterozygotes. In diseases primarily involving the bipolar/Müller cell layer, 
a normal EOG would be expected. Therefore, the lowered EOG in 
heterozygotes'9, in contrast to our results, remains unexplained. 
Senior's syndrome is due to a pleiotropic gene with variable expressivity. In 
some sibships one child may show only a tapetoretinal dystrophy, and another 
only nephronopthisis'. Previous reports of four obligate carriers showed that 
the EOG was normal, borderline or low20'21. The authors of these reports 
suggested that the lowered EOG in heterozygotes indicates a carrier state. We 
examined two carriers and found the EOG to be normal in both cases (Tables 
1,2). 
Choroideremia is an X-linked recessive disease. Kurstjens performed EOG 
examination in 21 carriers, diagnosed either by the presence of typical 
ophthalmoscopic findings or by pedigree assignment22. The lower limit of the 
normal range of EOG was set at 185%ü. In three carriers the EOG was 
absent or showed no light-rise. The light-rise was normal in the remaining 18 
carriers. 
In the present study we examined, in addition to three previously reported 
cases23, 17 choroideremia carriers. The data are shown in Tables 1,2 and 
Figure 1. As expected, the EOG varied from abnormal to normal. 
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Choroideremia carriers as a group do not differ significantly from normal 
controls (p<0.20). 
However, in 24% of the carriers an abnormal EOG could be recorded. In the 
normal controls there is no correlation between the Lp/Dt ratio and age 
(p=0.51). In the choroideremia group however the Lp/Dt ratio significantly 
decreases with increasing age (p<0.05; Figure 1). We postulate that the 
carrier state of choroideremia is not a stationary condition, and with 
increasing age, visual function deteriorates very slowly, leading to an 
abnormal EOG in some. In addition there may possibly be two groups of 
earners: one with normal and one with decreased Lp/Dt ratio. 
We conclude that an abnormal EOG may indicate a carrier state in relatives 
of patients with some tapetoretinal dystrophies. 
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Stable and progressive hearing loss 
ABSTRACT 
Audiograms were traced or additionally performed on 23 Usher patients in 10 
Dutch multi-affected families, all linked to chromosome lq (USH2A locus). 
Serial audiograms, available in 13 patients, were used for a regression 
analysis of binaural pure tone average (BPTA) on age (follow-up period 
9-32 y) to test for 'significant progression', i.e., a significant regression 
coefficient, here called the 'annual threshold increase' (ATI, expressed in 
dB/y). A significant ATI (> 1 dB/y) was observed in 3 patients. Analysis of 
variance of ATI demonstrated significant heterogeneity; hearing loss was 
either stable or progressive. This implies a significant clinical heterogeneity. 
A similar analysis performed on our progressive USH2A cases and 'type III' 
cases previously reported on by others (ATI 1-5 dB/y), some of whom were 
recently linked to chromosome 3q (USH3 locus), failed to show any 
significant heterogeneity in the progression of hearing loss. 
INTRODUCTION 
Usher syndrome is an autosomal recessive disorder, characterized by con-
genital sensorineural hearing loss (SNHL) which is combined with 
progressive pigmentary retinopathy that shows onset in childhood or 
adolescence and leads to severe constriction of the visual field (tunnel vision). 
Cataracts usually occur later and cause additional loss of vision, eventually up 
to the point of (sub)total blindness. 
Three clinical subtypes were currently distinguished, before the gene-linkage 
studies started1'3. Type I shows profound congenital SNHL which causes 
abnormal speech and language development, combined with vestibular 
areflexia or severe hyporeflexia, which later in life adds to the problem of 
spatial disorientation as the visual system further deteriorates. Type II shows 
moderate to severe SNHL, most pronounced at the higher frequencies, 
whereas at the speech frequencies there generally is sufficient hearing ability 
to allow for the normal development of speech and language. Vestibular 
(caloric) responses can be elicited. The SNHL of this type was defined to be 
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stationary throughout life, apart from the development of presbycusis at a 
more advanced age. A clinical type of Usher syndrome with features similar 
to type II, in which however the SNHL proved to be progressive, was 
designated as type III. 
Gene-linkage studies have splitted up type I in 3 and type II in 2 subtypes. 
Type I has been linked to loci at 14q32 (USH1A)4"6, l l q H (USH1B)5"6 and 
l ip 13-15 (USH1C)6, whereas type II has been linked to lq41 (USH2A)7"9. 
Usher patients who failed to show linkage to chromosome lq41 are classified 
as Usher type 2 B 1 0 " . 
This study shows the long term results of audiometry in 23 patients from 10 
Dutch multi-affected families with Usher type 2A syndrome. Serial 
audiograms were collected and analyzed to evaluate whether the type of 
hearing loss was stable or showed significant progression. 
PATIENTS AND METHODS 
Our study population comprised 23 patients from 11 different sibships in 10 
kindreds with more than 1 affected person. Blood samples from affected 
persons and their non-affected relatives whose medical history indicated 
stable hearing loss (type II) were collected and analyzed in Boys Town 
National Research Hospital for gene linkage. The following chromosome 1 
markers had been typed on all family members: D1S245, D1S70, D1S217, 
D1S237, D1S229, D1S227, PPOL and D1S81. The Usher 2A gene is flanked 
by a 2.4 cMo region bounded by D1S237 and D1S229. 
History was taken and a general otorhinolaryngologic examination, including 
audiometry and collecting previous audiograms, was performed with otoscopy 
in all instances and the diagnosis of Usher's syndrome was confirmed by one 
ophthalmologist with assessment of the extent of retinitis pigmentosa, impair­
ment of the visual fields, visual acuity, dark adaptation testing and an electro-
retinogram. Vestibular excitability was confirmed with rotatory tests and 
caloric tests. This report will be limited to the evaluation of the audiometrie 
data. 
Audiometrie data could be obtained from the files from the Nijmegen ORL 
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Department or elsewhere. In all these cases clinical routine or serial audiom­
etry was performed according to common standards and with the usual 
clinical equipment. Serial audiometry over 9 years up to 32 years was 
available in 13 patients. Most of the patients were also examined in the 
University Hospital Nijmegen, where pure-tone audiograms were measured 
with an Interacoustics AC5 audiometer (Interacoustics, Assens, Denmark), 
calibrated following the ISO 38912 procedure according to the ISO 8253-1 
standard13 over the most recent years. The following tentative audiologic 
phenotypes were distinguished: type II (stable hearing loss), type III 
(progressive hearing loss), and 'mixed' (different types occurring simul­
taneously in one family). The assignment of each sibship was established by 
inspecting plots of the binaural pure tone average (BPTA, in dB HL, i.e. 
hearing level) against age; BPTA is the average of the pure tone average 
(PTA, at the frequencies 0.5, 1 and 2 kHz) of both sides. This tentative 
phenotype was used to test in first approximation whether it discriminated 
between the linked and unlinked subtypes of Usher type II. Statistical tests on 
audiologic data comprised a regression analysis of BPTA on age to see 
whether the regression coefficient - here called 'annual threshold increase' 
(ATI) and expressed in dB/y - differed significantly from zero in each 
individual with sufficient (n=>3) serial audiologic data available, and an 
analysis of variance of the ATI values to test for (non)homogeneity in type of 
hearing loss. 
RESULTS 
There were 11 different families and 10 different kindreds (the families H 
and I were the same kindred) with Usher type 2A. Two of the families 
involved multiple sibships of affected persons and the lod score data for these 
families represent linkage analysis on the whole kindred and are not presented 
on an individual sibship basis. The heterogeneity analysis (Ott's Α-test) was 
employed to determine the probability that each family was linked to a 
chromosome 1 q marker set. The overall χ2 was nonsignificant when only the 
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10 Dutch families were included and the resulting individual probabilities of 
each family being type 2A were all estimated at 1.0. Only when the Dutch 
data were pooled with the total set of 68 Usher II families ascertained world­
wide, were conservative probabilities obtained (the overall rate of 
heterogeneity was estimated at 12,5%). The resulting probabilities are shown 
in Table 1 and indicate that none of the families showed convincing 
nonlinkage with lq41 markers. Family M had the lowest probability, 0.955, 
because it was the least informative of all the families. 
Table 1. Summary diagnostic and linkage data for each multiplex sibship/kin-
dred analyzed. Phenotype II, stable hearing loss; phenotype III, pro­
gressive hearing loss; mixed phenotype, phenotype III does occur, 
but not - with at least some certainty - in all sibs. 
Family 
A 
В 
С 
D 
E 
F 
G 
H andl 
К 
M 
Probability of 
Linkage to 
lq41 markers 
0.985 
0.980 
0.972 
0.979 
0.979 
0.997 
0.972 
0.993 
0.996 
0.955 
Tentative 
Audiologic 
Phenotype 
II 
II 
III 
II 
II 
Mixed 
II 
Mixed 
Mixed 
II 
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Table 2. Multipoint lod scores of Dutch families grouped by audiologic 
phenotype. 
Group Family Distance in cMo from D1S237 
-10 0 +2 +12 
II A,B,D,E,G,M 2.485 3.535 3.463 2.438 
III С 0.414 0.582 0.683 0.415 
Mixed F.H&I.K 2.800 3.834 3.876 2.838 
Total 5.699 7.951 8.022 5.691 
As a further test of heterogeneity, the families were divided into 3 groups, 
those where most members fit with the II phenotype with a stable hearing 
loss (families A,B,D,E,G,M), those fitting the III phenotype with a 
progressive hearing loss (family C), and those which seemed to be mixtures 
of the two phenotypes (families F,H&I,K). The lod scores for these 3 groups 
were summed at constant positions -10, 0, +2, +12 centimorgans relative to 
marker D1S237 and the results are listed in Table 2. An M-test analysis 
(Morton) was carried out on the grouped data. The result was χ 2 ( 2 ) =0.20, 
n.s.
14
 Thus, it is concluded that dividing the sample into different audiologic 
phenotypes does not uncover any genetic heterogeneity of Usher type II. Thus 
we would conclude that this clinical variability is not due to the involvement 
of two (USH) loci. 
The available audiometrie measurements are presented by age in Table 3; 
included is the assigned tentative audiologic phenotype. The mean difference 
between right and left PTA was only about 5 dB (SD about 4 dB). 
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Table 3. Hearing loss, measured by the BPTA (dB HL), and regression on 
age (у, mo) and assigned tentative audiologic phenotype. The annual 
threshold increase (ATI) equals the regression coefficient; SD is its 
standard deviation. Italics indicate a significant difference from 
zero; the line types ( , ) refer to figure 2. 
Person Sex Age (y,mo)/BPTA (dB) Audiologic Regression parameters 
phenotype r ATI SD 
(dB/y) (dB/y) 
Al 
A2 
B3 
B4 
CS 
C6 
D7 
D8 
E9 
ЕЮ 
Fil 
FI2 
F13 
G14 
G15 
H16 
HI7 
118 
119 
120 
K24 
K.25 
F 
M 
M 
M 
F 
M 
M 
F 
F 
M 
F 
F 
F 
F 
M 
F 
F 
M 
F 
M 
F 
F 
43,0/60,48,11/64 1 
31,'/54, 44,11/65 I 
55,9/34 1 
24,5/32,40,6/42,40,10/48 1 
21,3/69, 26,5/73, 31,10/82, 36,10/84 1 
11,3/52, 13,5/61, 22,1/78, 28,1/82, 33,7/87, 1 
38,0/88 
11,4/48,26,5/48,27,3/53 1 
13,4/47,22,0/48,24,2/48 1 
6,10/49, 24,3/56, 25,3/58 I 
5,7/35, 13,3/33, 20,10/38 1 
5,7/48, 10,7/48, 14,4/54, 26,8/59, 37,3/87 I 
32,5/67, 34,9/62 1 
15,0/57,20,1/64,25,11/64 1 
39,9/61, 44,6/62, 48,9/62, 48,11/61 I 
45,8/58, 50,9/66 1 
45,4/88, 50,3/89 I 
42,10/81,45,10/86 1 
15,7/48, 22,8/54 1 
5,4/50, 11,5/48, 12,0/46, 21,3/53 1 
6,11/50,7,3/48,20,3/56 1 
40,2/58, 47,8/68, 49,10/61, 51,9/65 1 
41,10/95 I 
II 
II 
II 
I or III 
1 or III 
IP 
IP 
I or IIP 
II? 
0 94 
097 
0 95 
0.54 
0 98 
0.99 
0.59 
0 93 
0 85 
031 
0 52 
0 97 
0 80 
0 805 
1 04 
1 31 
0.174 
0 099 
0 450 
0 196 
Ul 
0 626 
0 041 
0 235 
0 529 
0 695 
0 305 
0.172 ... 
0 204 
0271 
0.019 
0.075 
0.266 
0.272 - - -
0 395 
0.090 
0.275 
0.143 
0 530 
M29 M 33,6/58, 38,6/62 II 
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.25 .5 1 2 4 8 kHz 
-·- Age 11 y 
^Age 13 y 
-s- Age 22 y 
-°- Age 28 y 
•*- Age 34 y 
-•-Age 38 y 
,38 y 
Figure 1. Serial audiograms of person Сб. The mean of the right and the left 
hearing level (air conduction threshold, dB HL) is shown. The 
regression line (BPTA on age) calculated from these values is: у = 
1.3lx + 42.7 (г = 0.95 for n=6, P= 0.0030), which indicates an 
ATI of about 1.3 dB/y (Table 3). 
A systematic study of the separate sound frequencies showed that the 
progression of hearing loss (when present) could be regarded as being suf­
ficiently represented by the progression at the speech frequencies (0.5, 1 and 
2 kHz), especially at 1 kHz. It was thus validated that the PTA (and hence 
the BPTA) was a suitable measure of the development of hearing loss. 
Those patients (n=13) were selected from whom sufficient serial audiograms 
were obtained to analyze the regression of BPTA on age. The ATI (expressed 
in dB/y) is the regression coefficient. An example of serial audiograms is 
shown in Figure 1. Histograms and probit plots (not shown) indicated the 
existence of two separate clusters of ATI values, those pertaining to cases 
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120 
100 
80 
60 
40 
20 ( 
BPTA (dB HL) 
* -к-" H ' " 
) 10 20 30 40 
h-* 
г 
* 
50 
age 
• A1.A2 
и ВЗ.В4 
* С5.С6 
0
 D7.D8 
х Е9.Е10 
* F11.F12.F13 
* G14.G15 
* Н16.Н17 
Il · 118,119,120 
(У) 
т
 К24.К25 
* М29 
Figure 2. Plot of BPTA as a measure of hearing loss against age for all of 
the available data (Table 3). All the separate data points are 
shown. Continuous fat lines connect individual longitudinal data in 
the 3 patients with significant progression as apparent from their 
ATI (C5...., C6 , and Fl I - - -) . Dashed thin lines connect 
individual longitudinal data in other cases. 
BPTA (dB HL) 
120 
100 
10 20 30 40 
age (у) 
— Gorlin 
* case 1 USH3 
•*• case 3 USH3 
-°- case 4 USH3 
"*" case 5 ? 
-•- case 7 ? 
-ь- case 8 ? 
-s- Sankila USH3 
• II-2 USH2A 
• II-4 USH2A 
-0-II-5 USH2A 
Figure 3. Plot of BPTA against age for previously reported patients, most of 
whom have been designated as Usher type HI, with sufficient 
follow-up data to allow regression (solid lines) or trend (dashed 
lines) analysis (Table 4). The data for patients II-2, 4 and 5 were 
obtained from Dr. Pakarinen (family 7, personal communication 
1995). 
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Table 4 BPTA and regression on age for previously reported patients for whom 
sufficient follow-up data were available Italics indicate significant values 
Reference 
Case no 
Gorlin et al" 
(one case) 
Kanalainen et al16 
Case 1 
Case 3 
Case 4 
Case 5 
Case 7 
Case 8 
Sankila et al" 
Case I I I , family 15 
Pakannen et al"" 
Case II 5, family 7 
Age (y)/BPTA (dB) 
4/57, 5/85, 9/90 
36/64, 44/63, 51/72 
9/52, 18/59, 32/72 
10/86, 24/102, 31/105 
9/28, 20/62, 27/71 
5/63, 13/77, 17/113 
7/59, 8/75, 15/92 
7/55, 8/80, 10/97, 
18/98, 18/108 
35/73, 42/> 100", 
51/115 
Audiologic 
Phenotype 
III 
II 
III 
III 
III 
III 
III 
III 
III 
Genotype 
USH3' 
USH3' 
USH3" 
?" 
?" 
9" 
USH3 
USH2A' 
Reeression 
г 
0 75 
0 79 
I 00 
0 98 
0 98 
0 91 
0 92 
0 80 
= 2 6 
remarks 
ATI 
(dB/y) 
5 07 
0518 
0 875 
0 939 
2 45 
3 82 
3 50 
3 08 
SD 
(dB/y) 
4 41 
0 405 
0 041 
0 177 
0 487 
1 794 
1 443 
1 338 
Dr L Pakarinen, personal communication 1995 
not measured at 2 and 4 kHz (PTA right ear) 
without apparent progression (tentative type II, with a low ATI) and those 
pertaining to cases with a substantial ATI (tentative type III). 
There were 3 patients with an ATI value which differed significantly from 
zero, i.e. they showed significant correlation/regression (Table 3): C5, C6 
(also see Figure 1) and Fl 1; their ATI was in excess of 1 dB/y. The 
continuous fat lines connecting the separate data points for these 3 patients 
are shown in Figure 2 to illustrate the progressive character of their hearing 
loss. 
Analysis of variance on all of our cases with an ATI value available (n=13) 
demonstrated that these values showed significant heterogeneity (F= 2.44, d.f. 
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12 and 22, P= 0.033). A similar analysis showed significant heterogeneity 
(F= 2.01, d.f. 19 and 31, P= 0.041) also for the combination of the present 
group of patients with known ATI and the cases previously described by 
others for whom regression analysis could be performed and an ATI value 
could be obtained (Table 4). All of the latter cases had a progressive type of 
hearing loss reported to be type III Usher syndrome, except for case I of 
Karjalainen et al16. Interestingly, an analysis of variance performed on the 
previously reported and our own cases (i.e. C5,6,F11) for whom ATI was in 
the range of 1-5 dB/y, i.e. those who showed the most convincing progression 
of hearing loss, failed to show any significant heterogeneity in ATI values 
(F= 1.20, d.f. 6 and 15, P= 0.36; after the exclusion of Gorlin's case -
because of its large SD - F= 2.07, d.f. 5 and 14, P= 0.13). 
DISCUSSION 
There is little doubt that there is substantial variation in the Usher 2A 
audiologic phenotype and at least 2 different patterns are apparent, one stable 
to slowly progressive, i.e. in keeping with normal presbycusis19, and another 
more rapidly progressive. Progression was not apparent from the medical 
history. According to the χ2 test applied to the data presented in Table 2, the 
apparent audiologic phenotype did not appear to be associated with linked or 
unlinked subtypes. No evidence of families showing no lq linkage was in 
fact observed. However, the phenotyping used and thus the grouping of the 
families, was somewhat arbitrary. We therefore also performed analyses of 
variance on the ATI variable, i.e. for those patients for whom sufficient 
follow-up data were available. The latter analyses on the one hand clearly 
demonstrated heterogeneity in the progression of hearing loss in our patients, 
whereas on the other hand there was no significant difference in progression 
between our 3 patients with the most convincing progression and the similar 
cases previously reported for whom sufficient data were available. Perhaps 
there is still lack of sufficient data, but it should be emphasized that 3 of our 
cases and 1 case previously reported16'case3, showed significant progression. 
The Dutch families are homogeneous with regard to linkage and all are type 
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2A. Thus the source of variation in audiologic phenotype seen here is not due 
to different mutations at different USH loci (in as far as presently known and 
therefore screened in our patients). 
These results argue only that phenotypic variation in terms of the progression 
of hearing loss occurs within the Usher 2A sample of families. There is only 
a single previous report which noted no difference between the hearing loss 
seen in type 2A versus 2B10. Thus, an investigation into possible audiologic 
differences between the type 2A and 2B subtypes is in order. 
There are no linkage data published from families with the tentative clinical 
'type III Usher', i.e. progressive hearing loss, such as the patients described 
by Gorlin et al15 and Karjalainen et al16 whose hearing data were included in 
the present analysis (Figure 3, Table 4), with one exception. Most recently, in 
the Finnish population Usher syndrome type III has been linked to 
chromosome 3q (USH3 locus)17 and some of the cases included in our 
analysis (Table 4, Figure 3) recently turned out to be USH3. It seems that we 
have to face the situation that not only Usher 3 patients but also Usher 2A 
patients show, or may show, progression of hearing loss. Nevertheless more 
detailed and more numerous data on the audiologic features of Usher 3 
patients also based on gene linkage results will be needed to conclude more 
precisely whether those types can be divided clinically only on audiometrie 
data. 
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Ophthalmologie findings in Usher type 2A 
ABSTRACT 
Thirty-seven patients, comprising 24 familial cases and 13 isolated patients 
with Usher syndrome type II (USH2), underwent ophthalmologic 
examination. Based on the degree of hearing loss, normal vestibular function 
and gene-linkage analysis, familial cases were assumed to have USH2A. An 
analysis of genetic heterogeneity failed to reveal the presence of a second 
locus in the Dutch population. Although the patients appear to belong to a 
genetically homogenous group, remarkable ophthalmologic variability was 
found. Corrected visual acuity decreased with age and remarkable differences 
in visual acuity were found within one family. Fundoscopic findings were 
classified as type A if attenuated vessels and bone corpuscles in all quadrants 
were found or as type В if findings other than these were found. The 
prevalence of type A significantly increased with age. 
INTRODUCTION 
Usher syndrome is an autosomal recessive disease characterized by retinitis 
pigmentosa (RP) and bilateral congenital sensorineural hearing loss or 
deafness. The prevalence of the Usher syndrome is estimated at 3.0-
4.4/100,000'"5. It is the most frequent cause of deaf-blindness. Based on the 
clinical symptoms, three different types have been distinguished. 
Type I presents with deafness, RP, and loss of vestibular function. Type II 
has a mild to moderate hearing impairment, RP, but no vestibular 
dysfunction. Type III is characterized by progressive sensorineural hearing 
loss. Gene-linkage analysis has subdivided the clinical Usher type I into 3 
types (USH1A, USH1B, USH1C)6"8. USH1B has been found to be due to 
mutation in the myosin VIIA gene on chromosome 1 lq9. Most Usher type II 
families show linkage to chromosome lq41 (USH2A)10, although a few 
families have failed to show linkage to this region so far (USH2B)"·12. 
Usher type III has recently been assigned to chromosome 3q13. 
All 37 affected patients in this study are of Dutch nationality and were 
considered to have the USH2A based of physical examination and gene-
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linkage analysis. They were all carefully examined to study the variability in 
clinical symptoms. Remarkable variability was found in the ophthalmological 
symptoms. Therefore, this study focused on the ophthalmologic aspects of 
Usher syndrome. 
PATIENTS AND METHODS 
In total, 37 Dutch individuals with Usher syndrome type II were included in 
this study. Twenty-four patients came from families with more than one 
affected person (familial cases) and/or from families with close consanguinity. 
These families were listed alphabetically from A to N and the patients were 
numbered consecutively. Family H/I is considered to be a special family. 
Patient H17 is married to patient 1, who is an isolated case of Usher type II. 
They have three children with the Usher syndrome (family I). The other 13 
patients of the 37 patients were the only affected persons in their respective 
families. They are called isolated cases and are listed 1-12B. Case 12A and 
12B are monozygous twins (Table 1). 
The diagnosis of the Usher syndrome was confirmed by medical history and 
otoscopie, audiovestibular and ophthalmologic examination. The presence of 
vestibular reflexes and the degree of their sensorineural hearing loss 
confirmed the clinical diagnosis Usher syndrome type II. Blood was sampled 
from the patients, their sibs and their (grand)parents and sent for gene-linkage 
analysis to Boys Town National Research Hospital (Omaha, NB, USA). All 
familial cases showed linkage to chromosome lq41. No linkage to 
chromosome 3q was found. An analysis of linkage heterogeneity of 
informative families did not support the hypothesis that there are cases 
unlinked to lq41 markers. Thus it is assumed that the familial cases as well 
as the isolated cases are USH2A. 
All patients underwent ophthalmologic examination including corrected visual 
acuity measurement, slit-lamp examination and ophthalmoscopy. One 
ophthalmologist performed the ophthalmoscopy in all the patients in order to 
obtain consistent results. Visual fields were evaluated with the Goldmann 
perimeter, using test targets 1-1, 1-4, III-4 and V-4. Electro-oculographic 
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(EOG) and electroretinographic (ERG) examinations were performed as 
previously reported1415. 
Statistical analysis was used to verify the variability between the two patients 
groups, i.e. familial and isolated cases, and within each group. Differences in 
the relative frequencies of any feature were tested in a 2x2 contingency table 
using Fisher's Exact Probability test; the F value (cf. Ρ value) is specified 
only for significant differences (i.e. F< 0.05). 
RESULTS 
The results of the otoscopie and audiovestibular examination of the 13 
isolated cases and all but 3 familial cases are in accordance with the 
characteristics of Usher type II. The results of the familial cases have been 
described previously, in three Usher type 2A cases (C5,C6,F11) a progressive 
hearing loss was observed16. 
Table 1 shows the results of the ophthalmologic examination. The corrected 
visual acuity ranged from 1.0 to light perception only. As could be expected, 
visual acuity decreased with age (Figure 1). Cataract formation could be 
demonstrated in 7 out of the 24 familial cases and in 3 of the 13 isolated 
cases. The most common form of cataract was Cataracta corticalis posterior 
(CCP). 
It is now generally accepted in all forms of RP that different fundus 
appearances may be seen within families and classifications of disease based 
on fundoscopic appearances were until now not helpful. We also observed a 
remarkable variety of fundoscopic findings in the familial cases as well as in 
the isolated cases. In an attempt to correlate gene linkage results with 
fundoscopic appearance, we classified the fundoscopic findings as type A and 
type B. A type A fundus was defined as being characterized by narrow 
vessels and bone corpuscles in all quadrants and could include yellow, grey-
white flecks, atrophic patches, or a tapetal sheen. Findings other than these 
were called type B. Within a family, type A as well as type В fundi were 
observed (families B,C,D,F,K). 
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Table 1 Results of the ophthalmologic examination of 37 Usher type II patients 
Patient Age Sex Corrected visual acuity Fundus Media Goldmann EOG ERG 
48 
A2 44 
ВЗ 55 
B4 40 
С5 35 
С6 38 
D7 27 
D8 24 
Е9 25 
F11 37 
F12 35 
П З 26 
HI6 50 
HI7 45 
118 22 
119 21 
OD 0 2 
OS 0 08 
OD 0 3 
OS 0 2 
OD 0 25 
OS 0 4 
OD 10 
OS 10 
OD 0 5 
OS 0 5 
OD 0 8 
OS 0 8 
OD 0 5 
OS 04 
OD 0 5 
OS 0 3 
OD 1 0 
OS 0 8 
OD 10 
OS 0 8 
OD 0 4 
OS 0 3 
OD 10 
OS 0 8 
OD 0 8 
OS 0 8 
OD 1θ00 
OS 1/300 
OD <0 5/300 
OS <0 5/300 
OD 0 4 
OS 0 3 
OD 0 3 
OS 0 5 
M OD 0 6 
OS 0 8 
OD 0 5 
OS 0 5 
CCP 
CCP 
CCP 
IO 
CPP 
ce 
CCP 
CPP 
N 
N 
N 
N 
CCP 
CCP 
CCP 
IO 
OS large 
vacuole 
CCP 
N 
N 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
5° 
5° 
10° 
5° 
TV 
TV 
TV 
TV 
20" 
20° 
10" 
10" 
20" 
20" 
25° 
25° 
PRS 
PRS 
PRS 
PRS 
20° 
20° 
20° 
20" 
PRS 
PRS 
30" 
PRS 
TV 
TV 
25° 
25° 
25° 
25° 
ODS decr 
sensitivity 
OD 
OS 
20" 
20" 
RRS (1/4) 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
108 
104 
122 
138 
0 67 
0 50 
100 
100 
1 I I 
100 
0 62 
0 60 
100 
100 
100 
0 88 
0 86 
1 12 
1 10 
108 
100 
0 83 
0 95 
1 00 
0 95 
125 
0 97 
0 83 
1 00 
1 00 
0 90 
0 86 
1 14 
109 
0 93 
0 95 
1 55 
100 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
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Panent Age Sex Corrected visual acuity EOG ERG 
120 20 
K21 91 
K22 43 
M23 38 
N24 59 
1 49 
26 
30 
52 
35 
48 
II 28 
I2A 13 
I2B 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
OD 
OS 
0 8 
0 8 
0 5/300 
lightperception + 
05 
04 
2/60 
04 
0 1 
1/300 
0 08 
0 08 
08 
08 
10 
10 
0 1 
0 25 
0 6 
0 6 
0 05 
0 05 
0 25 
0 30 
0 25 
0 16 
10 
0 8 
04 
03 
05 
05 
10 
10 
10 
10 
nep 
CE 
ССР 
CSCP 
CSCP 
CE 
CCP 
CCP 
CSCP 
CSCP 
CSCP 
CCP 
CCP 
NC CCP 
CPP 
IO 
CSCP 
OD N 
OS N 
ODS nep 
ODS 25°+PRS 
OD 
OS 
OD 
OS 
OD 
OS 
nd 
nd 
nd 
nd 
nlr 
nlr 
ODS PRS+ OD 0 94 
central decr OS 1 00 
sensitivity 
OD 5" OD I 15 
OS 5° OS I 26 
OD 5° 
OS 5° 
OD PRS 
OS PRS 
OD PRS 
OS PRS 
OD 10° 
OS 10° 
OD PRS 
OS PRS 
OD 15° 
OS 15° 
OD 5° 
OS 5° 
OD PRS 
OS PRS 
OD 10" 
OS 10° 
OD 10° 
OS 10° 
OD PRS 
OS PRS 
nd 
nd 
OD nd 
OS nd 
OD < 1 8 
OS < 1 8 
OD 100 
OS I 14 
OD 123 
OS 133 
OD 100 
OS I 00 
OD 133 
OS 0 94 
OD nd 
OS nd 
OD 100 
OS 100 
OD 100 
OS 100 
OD 1 04 
OS 1 25 
OD 1 00 
OS I 00 
OD 125 
OS I 18 
OD I 25 
OS I 18 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS 0 
ODS sub­
normal 
ODS sub­
normal 
Abbreviations Media-Normal (Ν), Cataract Extraction (CE), Increased (lens)Opacifìcation (IO) Cataracta Corticalis Postenor (CCP) 
Cataracta Polaris Posterior (CPP), Cataracta Capsulans (CC), Nuclear Cataracta (NC), Cataracta Subcortical^ 
Posterior (CSCP), Goldmann Relative Ring Scotoma (RRS), Partial Ring Scotoma (PRS), Tunnel Vision (TV), No 
light response (n l r ) , No examination possible (nep) , not done (π d ) 
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corrected visual acuity 
0.8 
0.6 
0.4 
0.2 
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• • ж 
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0 10 20 30 40 50 60 
age (у) 
Figure 1. Corrected visual acuity related to age for multiplex (asterisks) 
and isolated cases (triangles). 
Analysis of the ophthalmoscopy results showed that a type A RP fundus was 
significantly more prevalent at a higher age than a type В fundus (Figure 2). 
This difference in prevalence was observed in the familial as well as in the 
isolated cases and in women as well as in men. Fourteen out of 17 patients 
with a type A RP fundus were older than 36 years, whilst only 6 out of 18 
patients with a type В RP fundus were in this age group (F = 0.0043). 
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# patients 
0 - 2 0 2 1 - 3 0 31 - 40 41 - 50 51 - 60 
age group (y) 
Figure 2. Distribution of type В (solid bars) and type A (hatched bars) 
fundoscopic findings per age group. 
Fundoscopic examination of patient H17 revealed attenuated retinal vessels, 
many subretinal white punctate deposits and hardly any bone corpuscles: a 
retinitis punctata albescens aspect. The patient's children and her sister all had 
a type В fundus but no retinitis punctata albescens dots. Results of Goldmann 
perimetry ranged from decreased sensitivity to tunnel vision of 5°. 
In all the patients, the EOG Lp/Dt ratio was < 1.80 (ranging from 0.50 to 
1.55), which indicated impairment of the function of the retinal pigment 
epithelium-rod complex. The ERG was extinguished in all the affected 
persons except for patients 12A and 12B who both had subnormal rod and 
cone function. This was in accordance with the early stage of their RP. 
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DISCUSSION 
Several authors have focused on the similarity and variability within 
populations with Usher syndrome. Even before detailed linkage analysis 
became possible, clinical similarity and/or variability was described within 
families. Hallgren1 and Davenport et al17 described familial similarity only 
with regard to auditory impairment. Bell18 mentioned that retinal pigmentary 
dystrophy may show remarkable intrafamilial similarity and De Haas et al19 
also recognized distinct intrafamilial similarities in the ocular disease pattern. 
On the other hand, studies by Nuutila2, McLeod et al20, Fishman et al21 and 
Bateman et al22 all stated intrafamilial variability with regard to the 
audiovestibular and/or ophthalmologic features (Table 2). Fishman et al21 
examined 24 Usher type I patients and found no intrafamilial variability with 
regard to the level of ocular, cochlear and vestibular impairment. However, 
when he examined 16 Usher type II patients, he observed intrafamilial 
variability in the degree of hearing impairment, peripheral field loss, and 
fundus pigmentations. 
Table 2. Survey of the literature on clinical variability/similarity. 
ENT Ophthalmology 
Author Year Type Hearing Vestibular Onset Perimetry Fundoscopy 
Bell18 
Hallgren' 
de Haas et a l" 
Nuutila2 
McLeod et al20 
Davenport et a l" 
Bateman et al22 
Fishman et al21 
1922 
1959 
1970 
1970 
1971 
1978 
1980 
1983 
-
-
I, II 
I, II 
II 
II 
II 
1 
II 
loss 
-
s 
-
s 
ν 
s 
-
s 
ν 
function 
. 
-
V 
-
-
-
-
s 
. 
nyctalopia 
-
-
S 
S 
ν 
-
ν 
s 
-
-
-
s 
-
ν 
-
ν 
s 
ν 
s 
-
s 
ν 
ν 
-
ν 
s 
ν 
Abbreviations: intrafamilial similarity (S); intrafamilial variability (V); 
no information available (-) 
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Visual acuity and visual field 
This study focused on the variability in ophthalmologic findings in a group of 
Usher type 2A patients. As illustrated in Figure 1, visual acuity decreased 
with age. Similar results have been described by Piazza et al23 and Fishman et 
al21. To compare our data with these latter studies, linkage data of these 
Usher patients should have been available. Within a family, remarkable 
differences were found in corrected visual acuity. This may be due to cataract 
formation (family B), but it also depends on the functional integrity of the 
macular area. As a result of differences in age, it is not possible to comment 
on the variability of the visual fields between individual patients. It is 
common knowledge that constriction of the visual fields will progress with 
age. 
Ophthalmoscopic findings indicated diverse fundus aspects in the examined 
USH2A patients. The age-related difference in prevalence between type A 
and type В RP fundus aspects was statistically significant. A type A fundus 
may evolve from a type В fundus with increase in age and duration of the 
desease. This does not exclude the possibility that a type A fundus can occur 
at an early age or that it will never develop, as was indeed found in some of 
the present familial and isolated cases (D7,H16,H17,K21,2,6). One reason for 
clinical heterogeneity is that more than one locus causes the disorder. At least 
two loci are known to be responsible for Usher type II, but the type unlinked 
to chromosome lq41 is uncommon and there is yet no evidence for its 
presence in the Dutch population. Hence, it seems unlikely that a second 
locus is responsible for the ophthalmologic variation observed in this study. 
Another possible explanation is that the clinical variability in fundus aspects 
relates to the presence of different mutant alleles, as has been described for 
the RDS gene24"26. Within a given family, type A and type В fundi can be 
found in sibships of approximately the same age (families C,D,F). Differences 
in the type of alleles involved cannot explain the variability within these 
sibships; this variability might be based on differences in genetic background 
or gene interactions27. Environmental influences may also play an important 
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role The isolation of the USH2A gene will contribute to understand the 
funduscopic variability observed in a USH2A population 
Ophthalmoscopic examination of patient HI7 revealed retinitis punctata 
albescens. Patient H17 is married to an isolated Usher patient (1). All their 
children are affected with the Usher syndrome, which makes it highly likely 
that the combination of hearing impairment and RP in patient H17 is due to 
Usher syndrome. Nuutila2 also described retinitis punctata albescens in 3 out 
of 47 patients with dystrophia retinae pigmentosa - dysacusis syndrome, a 
synonym for Usher syndrome Retinitis punctata albescens seems to occur as 
a variant form of RP classically observed in the Usher syndrome This study 
demonstrates that the ophthalmologic symptomatology in an USH2A 
population can vary widely. Generally, retinal pigmentation and vascular 
attenuation in all quadrants of the fundus increase with age. The relation 
between visual acuity and age (Figure 1) will be helpful when counseling 
patients with USH2A. However, long-term follow-up of these patients would 
be worthwhile to evaluate the clinical course and establish whether the 
genetic background plays a role in the clinical heterogeneity observed. 
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Colour vision in retinitis pigmentosa 
ABSTRACT 
In retinitis pigmentosa patients the effect of cystoid macular edema on colour 
vision was studied. The occurrence of cystoid macular edema decreases with 
increasing colour vision defect. The mutual proportion of the main types of 
colour vision defects remains stable until visual acuity has dropped to 0.5; at 
lower VA levels the number of red-green defects increases. Neither the 
finding of a blue-yellow colour vision defect in FM 100 Hue testing nor the 
appearance of anomaloscopic pseudoprotanomaly is influenced by cystoid 
macular edema. The authors conclude that cystoid macular edema in retinitis 
pigmentosa patients mainly affects visual acuity and not colour vision. They 
also noted a familial occurrence of cystoid macular edema. 
INTRODUCTION 
In typical retinitis pigmentosa (RP), the results of colour vision (CV) 
examination are reported variously as normal, type III blue-yellow defective 
or type I red-green defective, the latter being due to concomitant macular 
dystrophy'. 
The anomaloscope red-green midmatchingpoint (MMP) in RP patients as a 
population is shifted towards red if compared with normal subjects. Some 
patients present with pseudoprotanomaly. Pseudoprotanomaly in RP has been 
attributed to shortening of the outer photoreceptor segments2. Another 
explanation of pseudoprotanomaly is the reduction of the optical density of 
the cone pigments in disoriented photoreceptors^6. 
Red-shifted MMP's and pseudoprotanomaly are common in diseases where 
inflammation or serous leakage in the posterior pole is present7. In RP cystoid 
macular edema (CME) is not an uncommon finding. To our knowledge, 
however, there are no data available on the possible effect of CME on CV in 
typical RP patients. We therefore made a retrospective study of CV 
examinations in RP patients, with special attention to the relationship with the 
fluorescein angiographic presence or absence of CME. 
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SUBJECTS AND METHODS 
From the CV files we selected 49 patients, examined in the period 1974-
1990, who were diagnosed as typical RP. The inheritance pattern in most 
cases was autosomal recessive or X-linked recessive. In some cases no 
definite inheritance pattern could be established but there was familial 
occurrence (multiplex cases)8. An important selection criterion was that 
fluorescein angiography had to be done and that the delay between the 
angiography and CV examination did not exceed 3 weeks. 
All the patients underwent complete ophthalmological examination, including 
corrected visual acuity (VA) measurement, slitlamp examination, 
ophthalmoscopy, visual field examination with the Goldmann perimeter, 
electro-retinography and electro-oculography. CV examination was under 
standardized conditions: 6 Philips fluorescent tubes colour 57, colour 
rendering index 96, providing 1,750 lux at the level of the tests. A test 
battery was used, composed of plate-tests, the FM 100 Hue test and 100 Hue 
derivative tests9. Anomaloscope examination, with the Nagel Modell II or the 
Neitz ОТ anomaloscope, was performed according to the Linksz procedure10. 
Pseudoprotanomaly was diagnosed if for all the equations the quotient of 
anomaly was <1.0, and if the fall of luminance from the green end to the red 
end of the equation zone was at most two arbitrary scale units". A fall of 
luminance or more than two scale units was considered to be an expression of 
pathologic scotopization12. 
RESULTS 
The results of CV examination in the 98 eyes are shown in Table 1. CME 
was present in three main groups: normal CV (40%), type III blue-yellow 
defect (33%) and combined blue-yellow and red-green defect (26%). 
In 77 eyes (79%) of the selected 98 eyes anomaloscope examination was 
reliable. The MMP's of these eyes are graphically represented in Figure 1. 
Table 2 demonstrates that 34 eyes (44%) presented with a MMP that was 
shifted towards red. Only 9 eyes of the 34 eyes with MMP <1.0 had 
pseudoprotanomaly and 3 eyes scotopization (Table 2B). 
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Table 1. Colour vision in retinitis pigmentosa (N = 98 eyes). 
Colour vision Eyes CME (%) 
Normal 
Sensitivity decrease 
Blue-yellow defect 
Blue-yellow + red-green defect 
Red-green defect 
30 
4 
30 
31 
3 
12 
2 
10 
8 
1 
40 
50 
33 
26 
33 
Total 98 33 34 
N 
u 
m 
b 
e 
r 
30. 
27
_ 
24 
21 
18
. 
15 
12 
9 
6 
3 
0 
15 
MMP in Retinitis Pigmentosa 
Γη ря Γψλ nfô гЩ μτψ • J Ш1Ш. rprpnlrfi 
14 13 12 11 10 9 8 
MMP (quotient χ 0.1) 
DCME ИпоСМЕ 
Figure 1. Anomaloscope midmatchingpoint in 77 eyes with retinitis 
pigmentosa, with (dotted bars) and without (hatched bars) 
cystoid macular edema. 
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VA in these eyesranged from 0.3 to 0.8. 
The group of 77 eyes with reliable anomaloscope examination could be 
subdivided into a subgroup of 22 eyes with CME and a group of 55 eyes 
without CME (Table 3). In 41% of the eyes with CME the MMP was shifted 
towards red, while this was the case in 45% of the eyes without fiuographic 
evidence of CME. 
The results of the FM 100 Hue test in 74 eyes are listed in Table 4. The 
mutual proportion of the types of CV defect is virtually the same in the VA 
groups 1.0-0.7 and 0.6-0.5: about half of the eyes has normal CV, about one 
third shows a blue-yellow defect, while a minority has a concomitant red-
green axis. 
Table 2A. Retinitis pigmentosa visual acuity (VA) versus diminished red-
sensitivity (MMP<I.0), (N = 34 eyes). 
VA 0.9 0.8 0.7 0.6 0.5 MMP 
1.0 1 
0.9 1 - 1 
0.8 2 1 1 - -
0.7 1 
0.6 3 3 3 1 -
0.5 2 - 1 1 
0.4 - 3 2 - 1 
0.3 2 - 1 
0.2 1 1 
0.1 1 
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Table 2B Retinitis pigmentosa visual acuity versus MMP in cases with 
pseudoprotanomaly or scotopization (N = 12 eyes) 
VA 09 08 07 06 05 MMP 
10 . . . . 
09 -
08 - - Γ -
07 . . . Ι­
Ο 6 1 1 3" 1 
05 - 1 - -
04 . ι . . 
03 - - 1 -
02 -
0 1 . . . . 
Abbreviations * eyes with anomaloscopic scotopization 
Table 3 MMP in retinitis pigmentosa cases with (+) or without (-) CME 
(N=77 eyes) 
CME+ 
CME-
(N=22) 
(N=55) 
MMP > 1 0 
MMP < 1 0 
MMP > 1 0 
MMP < 1 0 
13 eyes 
9 eyes 
30 eyes 
25 eyes 
(59%) 
(41%) 
(55%) 
(45%) 
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Table 4. FM 100 Hue results in retinitis pigmentosa. 
Colour vision 
Normal 
BY-defect 
RG-defect 
Colour vision 
Normal 
BY-defect 
RG-defect 
Total 
Colour vision 
Normal 
BY-defect 
RG-defect 
Total 
VA 
VA 
VA 
A 
1.0-0.7 
η 
9 
7 
4 
В 
1.0-0.7 
η 
7 
4 
4 
15 
С 
1.0-0.7' 
η 
2 
3 
0 
5 
(%) 
(45) 
(35) 
(20) 
(%) 
(46) 
(27) 
(27) 
(32) 
(%) 
(40) 
(60) 
(0) 
(18) 
All cases, N = 
0.6-0.5 
η 
14 
12 
6 
No С ME, N = 
CME, 
0.6-0.5 
η 
6 
10 
5 
21 
Ν = 27 
0.6-0.5 
η 
8 
2 
1 
11 
:
 74 eyes 
(%) 
(47) 
(37) 
(16) 
:
 47 eyes 
(%) 
(28) 
(48) 
(24) 
(45) 
eyes 
(%) 
(73) 
(18) 
(9) 
(41) 
0.4-0.1 
η 
3 
4 
15 
0.4-0.1 
η 
0 
0 
11 
11 
0.4-0.1 
η 
3 
4 
4 
11 
(%) 
(14) 
(18) 
(68) 
(%) 
(0) 
(0) 
(100) 
(23) 
(%) 
(28) 
(36) 
(36) 
(41) 
Abbreviations: *: best corrected VA in CME+ eyes was 0.8. 
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In the lowest VA group 0.4-0.1, due to eccentric fixation, the amount of red-
green defects increases to two third of the eyes (Table 4A). If we subdivide 
into two groups, with absence or presence of CME, it can be noted that 
(Table 4B, C): 
the best corrected VA in CME eyes was 0.8; 
type III blue-yellow defects are equally distributed among the 
two groups: 
30% (14 or 47) in the CME— group and 33% (9 of 27) in the 
CME+ group; 
about half of the eyes (13/27 = 48%) in the group with CME 
has normal CV; 
about half of the eyes (20/47 = 43%) in the group without CME 
shows a red-green axis, and 
CV is better in the CME group (48% versus 28%), but VA is 
worse. 
DISCUSSION 
In an extensive study on acquired CV defects the late Verriest reported on 
typical RP13. He stated that in cases with normal VA, a mild blue-yellow 
defect may occur. If VA has dropped to 0.7 or less, the blue yellow defect is 
moderate. If VA has dropped to 0.1 the CV defect becomes severe. Table 4A 
shows that the mutual proportion of the types of CV defect virtually remains 
stable until VA has dropped to 0.5. If VA has dropped further the number of 
CV defects with concomitant red-green axis increases rapidly. The Tables 1 
and 4B, С show that the CME tends to disappear in the more advanced stages 
ofRP. 
In 1982 one of us reported that RP patients may present with a blue-yellow 
CV defect whether or not there is CME14. The present study shows that the 
statement was correct (Table 4B, C), although there are differences between 
the FM 100 Hue results of the CME+ group and the CME— group. The 
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number of eyes in the different categories is small. 
In the Tables 4B and 4C we can see that the CME+ results are shifted to a 
lower VA group. We can explain the differences between the two groups if 
we assume that CME causes an extra drop of VA of at least two Snellen 
lines. 
According to some authors the Rayleigh match in RP is initially normal; later 
on pseudoprotanomaly becomes apparent2,4·615. An important part of the RP 
eyes indeed shows a red-shifted MMP (Figure 1; Table 2, 3). True 
pseudoprotanomaly occurred in one third of the eyes with a red-shifted MMP. 
Scotopization was found in 25% of the eyes presenting with 
pseudoprotanomaly. This is in agreement with a recent paper that reports 
scotopization in 32% of retinal diseases presenting with pseudoprotanomaly 
as sign of an acquired type III blue-yellow CV defect12. The last paper also 
states that there is no evident relationship between VA and scotopization12. In 
the present study only 3 eyes show scotopization (Table 2B); VA varied from 
0.6 to 0.8. Although this number is insufficient to allow any conclusion, it is 
not in contradiction with the reported observation. Diminished red sensitivity, 
pseudoprotanomaly and scotopization are symptoms of cone disorientation. It 
is not clear whether or not pseudoprotanomaly is an early stage of 
scotopization. 
A red-shifted MMP is seen in somewhat less than half of the RP eyes 
whether or not CME is present (Table 3). This finding is in favour of the 
supposition that CME does not affect the results of CV testing but, indeed, 
only VA. 
Finally we mention another and interesting observation of our study. We 
performed fluorescein angiography in two or more sibs of 6 different 
families. Surprisingly all sibs of a family had CME or all did not show CME, 
suggesting that a hereditary factor might determine the appearance of CME in 
RP. 
Further investigations are necessary. If this observation holds true than the 
presence of CME might be a clinical key for a given hereditary type of RP. 
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The Usher syndrome: a temporal bone report 
ABSTRACT 
The bilateral temporal bones of a deceased 84-year-old man who had been 
suffering from the Usher syndrome were examined using light microscopy. 
Histopathologic examination disclosed degeneration of the organ of Corti that 
was most profound in the basal tum, degeneration of cochlear neurons in all 
of the turns, and severe loss of spiral ganglia in both cochleas. Endolympha­
tic hydrops of unknown cause and a functionally unimportant pit malformati­
on in the macular utricle were observed in the right cochlea. We compared 
the aforementioned findings with temporal bone reports cited in the literature. 
INTRODUCTION 
Usher syndrome is characterized by bilateral congenital perceptive hearing 
loss or deafness with retinitis pigmentosa (RP) and has an autosomal 
recessive mode of inheritance. Hearing loss and RP are common in the 
general population, but rarely are found in combination. 
In 1914, the ophthalmologist Usher1, noticed the familial occurrence of the 
anomaly and believed that the symptoms were a specific genetic entity. Later 
studies established the autosomal recessive mode of inheritance2'4. 
The prevalence of Usher syndrome in the general population is estimated to 
be 3 to 4.4 cases per ΙΟΟ,ΟΟΟ5"9. This syndrome is the most frequent cause of 
combined deafness and blindness; it occurs in 0.2% to 7.9% of deaf 
people10"13. 
The syndrome has different interfamilial grades of occurrence5 N 1 5. These 
findings have led to the syndrome being divided into at least two, and 
possibly four, subtypes15'18. So far, the most agreement has been reached 
about type I, characterized by RP with profound hearing loss and vestibular 
areflexia, and type II, characterized by RP, a moderately serious perceptive 
hearing loss (especially in the high frequencies), and a sensitive vestibulum. 
Two other types are assumed to occur: type III, characterized by progressive 
hearing loss19'21; and type IV, which is rare, with the phenotype of type II 
characterized by X-linked recessive inheritance22. 
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These clinical variations have led to the assumption that the syndrome is 
caused by two or more genes located at different sites on the genome. This 
assumption was confirmed by recent gene linkage studies; five loci are 
recognized for several types of Usher syndrome23"29. 
Few histopathologic studies of Usher syndrome have been done. We report 
the findings of temporal bone examination in a deceased patient with type I 
Usher syndrome and compare our findings with those cited in the literature. 
REPORT OF A CASE 
The patient had been born deaf or had become deaf at a very young age. 
From age 24 to 28 years he was an inpatient at a psychiatric hospital because 
he was unmanageable at home. As a result of slow, progressive visual loss, 
he became blind at age 45 years. 
From age 33 to 70 years, he lived in four different institutions for long-term 
care. He was then transferred to a deaf-blind institute for adults, where he 
remained until his death at the age of 84 years. 
The diagnosis of Usher syndrome was made by the consultant 
ophthalmologist at the deaf-blind institute. He found typical RP during a 
fundoscopic examination. At age 75 years, the patient underwent otologic 
examination performed by one of us (C.W.R.J.C.). Audiologic examination 
disclosed slight residual hearing in the right ear and serious down-sloping 
hearing loss in the left ear (Figure 1). In addition a retraction pocket was 
observed in the right ear with an early-stage cholesteatoma that had caused 
partial erosion of the incudostapedial joint. No otoscopie abnormalities were 
found on the left side. Surgical intervention was not done, and vestibular 
examination was not performed. 
At age 84 years, the patient died of metastasized carcinoma, probably 
originating from the digestive tract. Examination of the family pedigree to the 
fifth generation excluded consanguinity between the patient's parents. 
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Audiogram of patient with Usher syndrome at the age of 75 
years. Circle indicates air conduction in right ear; X indicates 
air conduction in left ear. 
HISTOPATHOLOGY 
The temporal bones were removed in Nijmegen (the Netherlands) 3 hours 
post mortem, after injecting formalin into the middle ears through the 
tympanic membrane. Both temporal bones were sent to the Massachusetts Eye 
and Ear Infirmary, Boston, for histologic preparation and interpretation. Serial 
horizontal sections of both bones were prepared by previously reported 
standard methods30. Tissue sections showed good histologic preservation and 
preparation. 
The spiral ganglia were graphically reconstructed by methods previously 
described31·32. The ganglion cell populations were determined for four 
segments of the cochlea (0 to 6 mm, 6 to 15 mm, 15 to 22 mm, and 22 to 32 
mm) by multiplying each count by 0.9 to account for double counting of cells 
lying at the interface between sections and by 10 to account for cells located 
in unstained sections. The bony labyrinths were fully formed and the 
periosteal, endochondral, and endosteal layers appeared to be normal. 
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Figure 2. Photomicrograph of the right (left, top and bottom) and left 
(right, top and bottom) ears of a patient with Usher syndrome. 
Both ears showed degeneration of the organ of Corti, loss of 
spiral ganglia cells and nerve fibers, and patchy degeneration of 
the stria vascularis. The right ear showed severe endolymphatic 
hydrops (original magnification x20 [left, top and bottom], x40 
[right, top and bottom]. S indicates saccule. 
Both cochleas showed advanced atrophic changes in the organ of Corti 
(Figure 2). Throughout most of the basal turn in each cochlea, the organ of 
Corti was missing. In the upper basal, middle, and apical turns, the organ of 
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Corti consisted of mounds of cells in which Hensen's cells, atrophic and 
partly collapsed pillar and Deiters' cells, and inner phalangeal cells could be 
differentiated. In both cochleas, nuclei were located in the area that would 
normally contain inner hair cells, but it was unclear whether these were inner 
hair cells. They might have been border cells or inner phalangeal cells. 
Moderate to severe patchy atrophy of the stria vascularis was seen, but it was 
unclear whether this was worse than average for age (Figure 3, left). The 
tectorial membranes and limbuses looked normal. The spiral ligament showed 
atrophic changes compatible with age. Reissner's membrane looked atrophic 
with decreased cellularity. On the right side, hydrops was present in all three 
turns; Reissner's membrane was distended into the midportion of the scala 
vestibuli (Figure 2, top left). On the left side, slight hydrops was presented at 
the extreme apical end of the cochlear duct. This was considered abnormal 
(Figure 2, top right). 
The neuronal counts were 11268 for the right ear and 14445 for the left ear 
(Figure 4). 
Figure 3. Left, Higher magnification of the stria vascularis of the right 
ear with patchy degeneration. Right, Macular utricle of the 
right ear with a pit in the macular epithelium, partially filled 
with statoconia (original magnification χ 2 50 [left], χ 170 
[right]). 
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Figure 4 Left, Counts of spiral ganglion cells by segment in the right ear 
of a patient with Usher syndrome 209 cells in segment 1, 557, 
segment 2, 256, segment 3, and 230, segment 4 Total (1252) 
was multiplied by 0 9 to account for double counting of cells 
lying at the interface between sections and by 10 to account for 
the cells located in the unstained sections, a total of 11268 
spiral ganglion cells Right, Left ear 249 cells m segment 1, 
861, segment 2, 227, segment 3, and 268, segment 4, a total of 
14445 spiral ganglion cells (original magnification 
χ 1605x0 9x10) 
The cochlear neuron population was diminished more than would be expected 
as a function of aging (Table 1) The loss for the right ear and left ear was 
40% and 23%, respectively, when compared with age-matched controls 
Neuron losses were 68% (right ear) and 59% (left ear) compared with normal 
neonates (Table 1) The spiral canals had a large central acellular area that 
extended through all the turns The neuron populations congregated at the 
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margins of this tubular acellular space. 
Both ears showed a loss of more dendritic nerve fibres than cochlear neuron 
cell bodies, which indicated that a retrograde neuronal degenerative process 
had occurred. 
The saccular and utricular maculae and all the cristae of both ears looked 
normal. In the right ear, a small pit was seen in the utricular sensory 
epithelium at the posterosuperior part of the macula (Figure 3, right). This pit 
was partially filled with statoconia. This seemed to be an embryogénie 
anomaly of no functional significance. 
Table 1. Cochlear neuron counts in patient with Usher syndrome 
compared with age-matched controls and normal neonates. 
Neuron Count 
Age-matched controls 
Patient 
Right ear 
Loss, % 
Left ear 
Loss, % 
Normal neonates 
Patient 
Right ear 
Loss, % 
Left ear 
Loss, % 
1 
2250 
1881 
17 
2241 
1 
4900 
1881 
62 
2240 
54 
Segment 
2 
7000 
5013 
29 
7749 
1 
13400 
5013 
63 
7750 
42 
3 
4775 
2304 
52 
2043 
57 
8200 
2304 
72 
2040 
75 
4 
4675 
2070 
56 
2412 
48 
9000 
2070 
77 
2410 
73 
Total 
18700 
11268 
40 
14445 
23 
35500 
11268 
68 
14440 
59 
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Viewed in their area cribrosa, the superior and inferior divisions of the 
vestibular nerves looked normal in both ears; their trunks and the cochlear 
nerves were avulsed from the internal auditory canals. The facial nerve 
looked normal throughout the temporal bone. 
The cochlear aqueduct was patent on the left side and obstructed with fibrous 
tissue on the right. This was considered functionally unimportant. The 
endolymphatic ducts were patent in both ears. The endolymphatic sacs had 
been avulsed from their foveate fossae during removal of the temporal bones. 
COMMENT 
Since 1927, this is the second case report on the type I Usher syndrome that 
details the histologic findings in temporal bones. Since 1906, 12 articles have 
been published about the temporal bone in 10 patients who were probably 
suffering from Usher syndrome33"42. In a few of these studies, it is doubtful 
whether the diagnosis of the Usher syndrome should have been made because 
of the gaps in the clinical data. For example, Alexander, quoted by Nager3"1, 
reported no objective audiologic findings, and Buch and Jorgensen35 did not 
report RP. These two reports have been excluded from our comparison. 
Because Usher syndrome is split into several genetic syndromes based on 
clinical features and gene linkage studies, it is likely that the pathologic 
abnormalities vary by type. The gaps in clinical data make it difficult to 
classify the patients (Table 2). In addition to vestibular function, the severity 
of hearing loss is a major discriminating factor in the subclassification of 
Usher syndrome. Our patient's condition can be classified as type I Usher 
syndrome because of his serious hearing loss and his vision symptoms. 
Admissions to psychiatric hospitals are also part of the syndrome. 
The condition of the patients described by Siebenmann and Bing33, Cremers 
and Delleman42, and Nager34 can be classified as type I Usher syndrome 
based on the hearing loss. The two patients described by Nager34 underwent 
vestibular testing, contrasted with the other patients and our patient, and the 
finding of vestibular hyporeflexia supports the diagnosis of type I Usher 
syndrome. The condition of the patients described by Belai36, Shinkawa and 
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Nadol39 (also described by Nadol4041 and Schuknechtj7) should be classified as 
type III based on the progressive hearing loss These three patients did not 
undergo vestibular examination 
The patient described by Schmidt38 with a 30 dB hearing loss for low 
frequencies and no response above 1000 Hz and was probably a patient with 
type II disease, data on progression of the hearing loss and vestibular findings 
are unavailable Histopathologic data are not reported in detail in a few 
studies3738, which makes it difficult to compare the study results 
The most important abnormalities in our patient and in previous studies were 
degeneration of the organ of Corti, the loss of cochlear neurons, and 
degeneration of the spiral ganglia The severity of the abnormalities varied by 
study, but in all reports, degeneration of the organ of Corti was most distinct 
in the basal turns 
Atrophy of the stria vascularis, as found in our patient, was also mentioned in 
most studies cited in the literature33 3 4 3 6 л 4 ' 42, but it was not found in the 
patient described by Shinkawa and Nadol39 Nager34 reported that his two 
patients had abnormalities of the stria vascularis and atrophy of the spiral 
vessels, especially in the basal tum, and atrophy of the terminal vessels of the 
spiral prominence Siebenmann and Bing33 reported vascular degeneration of 
the cochlea and the vestibulum that was most prominent in the cochlea 
Vestibular abnormalities were not observed in all studies Siebenmann and 
Bing33 described a patient with vestibular hyporeflexia who showed partial 
degeneration of the macular epithelium and especially the crista epithelium 
without any clear abnormalities of the nucleus vestibularis 
In Nager's34 first patient with vestibular hyporeflexia, utricular degeneration 
was found without nerve or vestibular involvement In the patient described 
by Belai36, a decrease in sensory epithelium was noted in the macular utricle, 
saccule, and three cristae When his tissue sections were reviewed by 
Shinkawa and Nadol39 no vestibular abnormalities were found 
A normal vestibulum was also found in the patient with type III disease 
described by Shinkawa and Nadol39 
In our patient with type I and the patient with type I described by Cremers 
and Delleman42, no vestibular abnormalities were found during light 
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microscopic examination that could have explained the vestibular areflexia or 
hyporeflexia characteristic of type I. Vestibular examination results were 
available for either patient to confirm this discrepancy. Vestibular findings 
were not mentioned in the studies by Schuknecht37 and Schmidt38. 
Our vestibular findings support the conclusion of Shinkawa and Nadol39. 
Basis on their findings and reports in the literature, they did not believe that 
the partem of cochlear and saccular degeneration (Scheibe's deafness) 
proposed by Konigsmark and Gorlin43 was associated with Usher syndrome. 
Brain tissue was examined in few studies33·3''42. Cremers and Delleman42 
examined the brain and brain stem and found no abnormalities other than 
slight cortical atrophy. In contrast, analogue changes were found in the 
patients described by Siebenmann and Bing33 and Nager34: severe atrophy of 
the primary acoustic center that extended into the peripheral cortex. 
Many authors believe that the pathologic abnormalities in the cochlea are too 
slight for the severity of the hearing loss33,34'36'38. It was assumed initially that 
the abnormalities in the cortex and brain stem, which were considered to be 
secondary to the cochlear abnormalities, might possibly explain the hearing 
loss3334. 
Using electron microscopy techniques, Shinkawa and Nadol39 and Nadol4041 
suggested another cause. In the apical segment of the cochlea of a patient 
with type II who had no degeneration of the organ of Corti under light 
microscopy, there seemed to be a significant decrease in the number of affe-
rent nerve endings in the inner and outer hair cells. 
In contrast, the histopathologic abnormalities in our patient corresponded with 
the severity of the hearing loss. 
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Mapping of the choroideremia-like (CHML) gene 
ABSTRACT 
The human choroideremia-like (CHML) gene and a locus for Usher syndrome 
type 2 (USH2) were recently mapped to the lq31-qter region employing 
physical mapping and genetic linkage studies, respectively. Using a human-
rodent hybrid cell line, we could refine the assignment of CHML in this 
study to lq42-qter. USH2 was shown to map to the same chromosomal 
segment as evidenced by the fact that D1S58, a polymorphic marker 
previously shown to be located proximal to the USH2 locus, was also 
assigned in the lq42-qter segment. To investigate a possible role of the 
CHML gene in the pathogenesis of USH2, we investigated 10 Dutch and 9 
Danish USH2 patients for point mutations in the open reading frame of the 
CHML gene. Employing polymerase chain reaction-single-strand 
conformation polymorphism analysis and direct sequencing, we found no 
disease-specific mutations. These results suggest that CHML is not involved 
in the pathogenesis of USH2. 
INTRODUCTION 
Choroideremia (CHM) is an X-linked eye disorder characterized by 
progressive dystrophy of the choroid, retinal pigment epithelium (RPE), and 
retina. The underlying gene was isolated by making use of positional cloning 
strategies4". The identification of a large number of submicroscopical 
deletions and several different points mutations in exons from the 3' part of 
the CHM open reading frame (ORF) in patients with classical choroideremia 
has established its pathogenic role in this eye disorder3'6'7'22. 
Employing the mouse homologue of the human CHM cDNA as a probe, we 
have recently identified a CHM-related gene, designated CHML5. The 
predicted CHML protein shows 87% similarity to the predicted CHM gene 
product (van Bokhoven et al, manuscript in preparation). CHML was 
localized to lq31-qter using a panel of human-rodent cell hybrids5. This 
chromosomal region is known to harbor a locus for Usher syndrome type II 
(USH2). Usher syndrome is an autosomal recessive disease characterized by a 
133 
Chapter 6A 
congenital hearing impairment and progressive visual loss. USH2 is the 
milder form of the two mayor types of the Usher syndrome; type I patients 
are profoundly deaf, whereas type II patients are moderately deaf. Type I 
patient lack vestibular function; type II patients do not. Two genes involved 
in USH1 have been localized to chromosome 11 and one gene to 
chromosome 146'7'21. In most families with USH2, linkage has been 
established with markers from Iq32-q418,10. Absence of linkage to this 
chromosomal interval was shown for at least one family, suggesting genetic 
heterogeneity15. 
Recently, the rat homologue of the human CHM gene was isolated by using 
functional cloning strategies118"20. The purified protein is part of a 
multisubunit enzyme known to attach geranylgeranyl groups to Rab proteins, 
a subset of small GTP-binding proteins. Preliminary results employing CHML 
protein synthesized in bacterial and insect cells suggest that it has a similar 
enzymatic function5". 
To refine the physical colocalization of CHML and TJSH2, we constructed a 
Southern blot containing £coRI-digested DNA of the human-rodent hybrid 
1/22AM43, which contains lq42-qter as its only material from human 
chromosome l2. This blot was hybridized with YNZ23 (D1S58), a probe that 
is known to be located proximal to the USH2 locus9. Probe YNZ23 
hybridizes to three characteristic EcoRl fragments in control male DNA, 
hybrid 2748, and hybrid 1/22AM43 (Figure 1A), suggesting a location in 
lq42-qter. The presence of the CHML gene in this segment was determined 
by using PCR analysis. Primers 555 χ 557 (Table 1; Figure 2) amplified a 
specific fragment from hybrid 1/22AM43, hybrid 2748, and control female 
but not from 578, a hybrid line containing the human X but no other human 
material (Figure IB). 
This result narrows the localization of USH2 and CHML to a small region of 
chromosome lq. Next, we investigated 10 Dutch and 9 Danish USH2 patients 
for PCR-SSCP variants of the CHML ORF. This analysis was facilitated by 
the fact that the ORF of the CHML gene lacks introns. 
The oligonucleotides listed in Table 1 were employed as described14,22. 
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Figure I. A. Southern blot analysis of EcoRI-digested DNA of cell lines 1/22AM43 
(lane I), 2748 (lane 2), HR4 (lane 3), male control (lane 4), and 578 
(lane 5). Hybrid 2748 contains human chromosome 1, but not the X 
chromosome; hybrid HR4 contains Xp21-qter, but not chromosome I; 
and hybrid 578 contains the human X chromosome, but not 
chromosome 1. The signal in lane I is relatively weak due to the fact 
that the translocation chromosome is present only in approximately 
40% of the cells of this hybrid (A.H.MG.v.K., unpublished data). 
B. PCR analysis of hybrids 2748 (lane 1), 1/22AM43 (lane 2), X/lPaC2 
(lane 3), female control DNA (lane 4), hybrid 578 (lane 5), HR4 
(lane 6), A3 (lane 7), and a control sample amplified without DNA 
(lane 8). Hybrid X71PaC2 contains human lpter-q3l, A3 is a 
hamster cell line. Prior to the PCR reaction, primer 555 was end-
labeled with fy-32PJATP. Samples were run in a 6% Polyacrylamide 
gel. 
550· 
0 
598- 551 
1 
438-
- ζς4 SSS-
439 570-
2kb 
— 557 
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Figure 2. Schematic representation of the segments amplified in the SSCP analysis 
including the flanking oligonucleotides. 
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Table 1. PCR-SSCP Primers of the CHML gene. 
Oligo No. Sequence (5'-3') Position 
in ORF 
550 CACCTCATTTCTTTCATCAG 
597 CATTGTTTTGCTGATACTCC 
598 GTTTCAGCTTTTCAGGATTG 
551 AGTGAAGGTATTAGACACCC 
5 71 TTG A AGAG ATTGGTGCTCTG 
599 TCATCGGCCTTATCTTCTAC 
600 GAGGAATCAGTGGAGAAGGA 
543 CCTTCTCGAAATGCAAGAATCC 
552 GCTGTATTCTCAAGGATTGC 
553 GTCATTGCAATTGAGTGCAG 
438 AGATCACATTTTATGAATATTTA 
439 CGAAGACAATAAATTCCACCAAA 
554 TTCAGTGTCTCGGACGGTTT 
601 GATCTGTAATGAGTACTGCC 
602 GTGCAGTATAAGCAGATCTC 
556 CCACAAGAGTCTTGGCTTTG 
555 GGACACCTATCTGGTACATT 
557 CTTCTGGATTTGGAGGTGGA 
570 CTGTGGCCTGGGAAATGAGC 
569 GAAGGAGGTCCAAAACAGCA 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
-50 
199 
146 
398 
338 
632 
517 
812 
711 
1037 
956 
1208 
1091 
1387 
1345 
1650 
1509 
1843 
1743 
2009 
Note Primers 438, 439, and 543 are CHM-specific primers The underlined 
nucleotides indicate the mismatches with the CHML gene 
The DNA fragments amplified from the ORF varied in size from 249 to 334 
bp. In view of the high degree of sequence similarity between CHM and 
CHML, several of the listed primers can also anneal to CHM sequences. 
However, based on the preliminary exon-intron map of the CHM gene, all 
amplified fragments from the CHM gene except the fragment amplified by 
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primers 571 χ 599, contain at least one intron. The relatively large size of 
these introns 4 · l b I i u n p u h l , , h e t i d a t a precludes efficient amplification of the X-
chromosomal sequences. A small but suspicious SSCP shift was observed for 
one patient (DU7) with the primer combination 571 χ 599, while other 
patients had an apparently normal SSCP band for this primer combination. To 
investigate the nature of this variant, we performed direct sequencing using 
the cycle sequencing protocol13. It appeared that patient DU7 had a silent A 
to G substitution at nucleotide position 438 (Ser146), which was not found for 
patient DU8 who was used as a control. Interestingly, in keeping with the 
autosomal recessive inheritance of the USH2 syndrome, the mutation in DU7 
is present in both copies of the CHML gene, or alternatively, the second gene 
copy is deleted in DU7. Hence, despite the fact that the A to G mutation does 
not affect the predicted CHML amino acid sequence, it is possible that the 
mutation interferes in another way with the normal expression of the CHML 
gene. For example, the A to G mutation may result in a suboptimal codon 
(TCG) for serine, change of secondary structure in the CHML mRNA, or 
activation of a cryptic splice site. To investigate the possible causative 
relationship between the mutation at position 438 and USH2, 6 other USH2 
patients and several control individuals were analyzed. Homozygosity for the 
A to G mutation was found for several of the USH2 patients as well as for 
normal controls, excluding that the A to G substitution underlies the USH2 
phenotype. Based on these results, we conclude that USH2 most likely is not 
caused by defects in the CHML gene. 
The SSCP analysis conditions we employed reveal approximately 80% of all 
mutations12. This, together with the fact that we have not yet investigated the 
5' and 3' noncoding regions as well as the promotor region, leaves the 
possibility that we are missing causative mutations. The formal exclusion of 
the CHML gene as a candidate gene for USH2 must await detailed RNA and 
protein analysis from B-cell lines of patients. 
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Gene mapping of Usher syndrome type 2A 
SUMMARY 
Usher syndrome type II is associated with hearing loss and retinitis 
pigmentosa but not with any vestibular problems. It is known to be 
genetically heterogeneous, and one locus (termed USH2A) has been linked to 
chromosome lq41. In an effort to refine the localization of USH2A, the 
genetic map of the region between and adjacent to the marker loci previously 
recognized as flanking USH2A (D1S70 and PPOL) is updated. Analysis of 
marker data on 68 Usher II families places the USH2A gene into a 2.1-cM 
region between the markers D1S237 and D1S229. The gene for transforming 
growth factor B2 (TGFB2) and the gene for the homeodomain box (HLX1) 
are both eliminated as candidates for USH2A, by virtue of their localization 
outside these flanking markers. The earlier finding of genetic heterogeneity 
was confirmed in 6 new families and the proportion of unlinked Usher II 
families is estimated at 12.5%. The placement of the USH2A gene into this 
region will aid in the physical mapping and isolation of the gene itself. 
INTRODUCTION 
Usher syndrome is a hereditary disorder that causes congenital hearing loss, 
progressive retinitis pigmentosa, and vestibular dysfunction. The disorder is 
clinically heterogeneous with at least two distinct phenotypes'. Usher type I is 
distinguishable from Usher type II on the basis of severity of hearing loss and 
extent of vestibular involvement: type I patients are profoundly deaf, whereas 
type II patients are "hard of hearing"; type I individuals have absent 
vestibular responses, whereas type II persons are normal in this regard. 
The frequency of Usher syndrome has been estimated at 3.0/100,000 in 
Scandinavia2,3 and at 4.4/100,000 in the United States4. The prevalence of 
Usher syndrome among deaf individuals has been reported to be 0.6-28%5. 
Conversely, the frequency of deafness in the retinitis pigmentosa population 
is estimated to be 0.8%-33.3%. 
One gene for Usher type II has been localized to chromosome lq, and Usher 
type I families failed to show the same linkage6,7,8, thus demonstrating that 
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the observed clinical heterogeneity of Usher syndrome is due to the effects of 
mutations in two or more separate and distinct loci. Subsequently, the 
genetics of Usher syndrome was found to be more complex. First came the 
discovery, with a set of Usher type I families in France, of a linkage to 
chromosome 149, and then came the subsequent discovery of two more Usher 
type I linkages, one to 1 lp and another to 1 lq, in other families10·11. It 
appears that two of the Usher type I linkages detect loci coding for less 
common types of Usher I, with mutations predominantly present in the people 
from the Poitou-Charentes region of France and the French Acadian 
population of Louisiana in the United States; these loci have been designated 
USH1A (14q) and USH1C (Up), respectively. The most common Usher type 
I mutation is found on a locus present on chromosome 1 lq (USH1B). Next 
came the discovery of an Usher type II family that failed to show linkage 
with markers on lq411 2. This observation has been extended here to include 
several other families and has important implications because it complicates 
the search for the USH2A gene. The Usher gene located on lq41 has been 
termed USH2A, and the one unlinked to that region has been designated 
USH2B. Thus, there are at least five different genetic loci involved in Usher 
syndrome - two coding for the milder Usher type II (one of which is linked, 
to 1 q41 ) and three coding for the more severe Usher type I. 
Although no overlap between Usher type I and Usher type II phenotypes has 
been observed in our large series of families, the linkage-based subtypes 
(Usher IA vs. IB vs. 1С and Usher IIA vs. IIB) cannot be clinically 
differentiated from one another. This is a report of further advances toward 
the identification of the Usher II type gene (USH2A) on chromosome lq41. 
FAMILIES AND METHODS 
Families 
Two hundred twenty Usher type II families, including 365 affected 
individuals, have been ascertained. Of these, 68 families were informative. 
All families have been collected from the United States, Sweden, England, 
Ireland, Italy, Columbia, Spain, and the Netherlands. The ethnic distribution 
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of the families is almost totally limited to persons of European extraction. 
Only one family included in the study is of mixed European and African 
background. Two families were from Colombia, and an additional two in the 
United States have Hispanic surnames. The final sample used in the analysis 
included 55 multiplex sibships and 13 simplex sibships. Within these families, 
381 individuals were sampled, a group that included 137 affected individuals. 
Clinical studies and sample collection 
As each family was ascertained, a full medical and genetic history was taken. 
Many affected individuals in the United States were brought to Boys Town 
National Research Hospital for a full clinical evaluation, including audiology, 
vestibular studies, ophthalmology (fundus examination, electroretinography, 
electrooculography, fluorescein angiography), ear/nose/throat examination, 
and dysmorphology. The diagnosis of retinitis pigmentosa in a family requires 
that at least one family member have a history of night blindness, progressive 
reduction of peripheral vision, diminished or absent electroretinogram, and a 
typical fundoscopic appearance of the retina. The distinction between the type 
I and II phenotypes was based on audiologic and vestibular results: a type II 
individual was defined as one with normal vestibular responses and a mild-to-
profound sloping hearing loss. Exceptions to this rule were not included in 
the present analysis. Also, families with patients showing atypical retinitis 
pigmentosa, unexplained mental retardation, or dysmorphic features were 
eliminated from the study. A more complete discussion of the clinical 
evaluation and rationale for the definition of the two clinical types of Usher 
syndrome have been given elsewhere1. 
Blood of informative family members was mailed to Omaha, where the DNA 
was extracted from pelleted nuclei by an Applied Biosystem 340A nucleic 
acid extraction machine. DNA from families collected in South Africa was 
extracted there and was sent to the United States for typing. 
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Molecular analysis 
PCR amplifications of target sequences were performed in a total volume of 
25 μΐ containing 200 ng of human genomic DNA, 50 mM KCl, lOmM Tris-
HC1 pH 8.3, 1.5 mM MgCl2, 0.01% gelatin, 200 mM dNTPs, 1 μΜ of each 
primer, and 1 unit of Taq DNA polymerase (Perkin Elmer Cetus). The MgCl2 
was lowered to 0.9 mM for PCR reactions containing TGFB2 primers. For 
polymorphism screening and genomic typing, genomic DNA was lowered to 
20 ng, and dATP was 2.5 μΜ with the addition of ІцСі of a32P-dATP (800 
Ci/mmol; NEN) to each reaction. All primers used in this study were 
synthesized on a Cruachem PS 250 automated oligonucleotide synthesizer 
using standard phosphoramidite chemistry. SSCP typing for the HLX1 locus 
was done according to the method of Nishimura et al13. 
Cytogenetics 
Blood specimens were cultured for prometaphase analysis by using a 
modification of the method of Ryback et al14. 
Genetic analysis 
Linkage analysis of DNA markers was performed by using the LINKAGE 
program, version 5.0315. Both two-point and multipoint analyses were done. 
The two-point results were done only to assure consistency and as a check on 
the multipoint results. LOD scores across the entire span of markers (i.e., 
D1S245 to PPOL) were generated by doing a rolling multipoint analysis 
using overlapping sets of five contiguous marker loci with the test locus 
(five-point analysis). The LOD scores plotted and used in the HOMOG 
analysis were those from the middle segment of each four-marker locus set. 
The pattern of inheritance of Usher syndrome was assumed to be recessive 
with full penetrance for the affected homozygote. The frequency of the Usher 
type IIA gene was assumed to be 1/140. The actual frequency of Usher type 
II is not known, but it is generally felt to be approximately the same as that 
for Usher type I. DNA marker haplotypes for normal and USH2 
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chromosomes were established by inspecting the parental chromosomes. 
Heterogeneity analysis was done with multipoint data generated as outlined 
above and using the HOMOG16 program. 
RESULTS 
Organization of the markers within the D1S170-PPOL region 
A genetic map of the USH2A region was constructed using marker data from 
the Usher type II families presented in this report. The markers in the region 
are listed in table 1, which also gives other pertinent information about each 
marker. All the markers are short tandem repeats (STRP); except for HLX1 
and D1S70, there are no other known RFLPs or VNTRs in the region. 
Table I. Characteristics of the chromosome lq41 dinucleotide repeat 
polymorphisms used in mapping Usher type IIA 
Locus No. of alleles Heterozygosity Size range (kb) Reference 
D1S245 
D1S70 
D1S217 
D1S556 
D1S237 
D1S229 
D1S227 
TGFB2 
D1S320 
ADRPT 
10 
4 
5 
12 
10 
8 
7 
5 
7 
6 
.83 
.62 
.66 
.83 
.77 
.78 
.68 
.52 
.70 
.63 
235-253 
179-185 
130-142 
109-139 
172-192 
191-207 
111-125 
156-168 
191-205 
85-99 
17 
18 
17 
19 
17 
17 
17 
20 
17 
21 
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Our data for D1S70 are a composite of results from typing both its RFLP and 
STRP sites.The SSCP polymorphism for HLX1 was typed in selected 
families, and, once it was found to crossover with Usher type IIA, its typing 
was discontinued. 
Although the recent reports of chromosome lq maps17'22'23; provide a good 
framework for mapping in that general region, there is still ambiguity 
regarding the relative positions of markers not common to the various 
published maps. In order to make use of all the marker data available, a 
combined map of the region, using all informative markers, needed to be 
constructed. We first attempted to determine the placement of the set of 
markers D1S245, D1S237, D1S229, and D1S227, relative to D1S70 and 
PPOL, the pair that previously had been found to flank the USH2A gene24. 
Since the order of the four Généthon markers had been established at > 
1,000:1 odds, the placement of D1S70 and PPOL within that group would 
yield an anchor map around which other new markers could be mapped. On 
the basis of existing maps, it was reasonable to expect D1S70 to be at or near 
the most proximal Généthon marker of the set, D1S245. 
Therefore, the three orders -D1S70-D1S245-D1S237, D1S245-D1S70-
D1S237, and D1S245-D1S237-D1S70- were tested by both multipoint 
analysis and meiotic mapping. Through multipoint analysis, the maximal 
LOD score observed for the placement of D1S70 between D1S245 and 
D1S237 was >3 over the maxima observed for the other two orders, thus 
establishing that order as D1S245-D1S70-D1S237. This conclusion was 
supported by direct gametic analysis. A similar approach was used to position 
PPOL within the Généthon set. The LINKAGE multipoint analysis placed 
PPOL distal to D1S227, with > 1,000:1 odds. This finding was also supported 
by haplotype analysis. Thus, the order of markers on chromosome lq was 
established to be D1S245-D1S70-D1S237-D1S229-D1S227-PPOL. 
Within this framework, we placed two addition markers, D1S320 and 
TGFB2. The results of a linkage analysis for TGFB2 and D1S320 indicated 
that both genes were between D1S227 and PPOL, with the location of each 
supported at a high degree of certainty. However, analysis of these two 
polymorphisms relative to each other yielded results that ordered the markers 
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D1S227-TGFB2-D1S320-PPOL at >100:1 odds. The order of TGFB2 relative 
to D1S320 was also supported by meiotic mapping. SSCP determination for 
HLX1 types was done only on families showing critical crossovers in the 
region; it showed no crossing-over with D1S320, and haplotype analysis 
placed it between TGFB2 and PPOL. HLX1 is not shown in the map order 
and distances given below, because only limited haplotype data were 
available for the analysis. 
Two moreproximal markers, D1S217 and D1S556, were also studied; both 
were found to lie between D1S70 and D1S237, at > 1,000:1 odds, and their 
order relative to each other is as indicated below, but with only -100:1 
certainty. 
The order of the final map constructed is D1S245 - 2.2 - D1S70 -1.9-
(D1S217 - 1.8 - D1S556) - D1S237 - 2.1 - D1S229 - 2.0 - D1S227 - 1.3 -
(TGFB2 - 0.3 - D1S320) - 0.3 - PPOL, in which the sex-averaged interval 
distances are presented in centimorgans. Markers in parentheses are those 
whose location is supported by the data, but not at 1,000:1 levels. These data 
are the result of analyses of-438 méioses in 74 two- and three-generation 
families, which includes both the 68 families with Usher type II that are 
reported here and 6 additional families (1 with recessive retinitis pigmentosa 
and 5 with atypical Usher syndrome families). The mapping results agree 
well with the estimates of order and distance that recently were reported by 
the CHLC data bank and the recent chromosome 1 workshop. 
The importance of locating TGFB2 and HLX1 outside the critical region for 
USH2A is that both have been suggested as candidates for Usher type II13. 
TGFB-like genes play a role in the normal development and differentiation of 
neural tissue, making them a logical candidate for Usher syndrome25·26. 
HLX1, though principally expressed in hematopoietic progenitors and 
activated lymphocytes, is expressed in fetal brain27 and could be considered to 
be involved in both auditory and retinal development. 
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Linkage of Usher type II gene and heterogeneity 
There are 68 families in the sample that have well-documented Usher type II. 
All families not fitting our clinical criteria' were excluded from this analysis. 
It was obvious from inspection of the haplotype data that linkage 
heterogeneity was present in the sample. 
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Figure 1. Pedigrees of six new Usher type II families that fail to show 
linkage to lq4I markers. The pedigree of the seventh family 
(i.e., family 735) has been published elsewhere12 and is not 
reproduced here. Markers distal to PPOL and proximal to 
D1S245 have been typed but are not shown. The thin line in the 
haplotype bar indicates a crossover. Designation of one 
chromosome as black and the other as white is done arbitrarily, 
with the only criterion being that one of the affected offspring 
had a pair of "black" chromosomes. All families show at least 
one obligate double crossover, given localization of USH2A 
between D1S237 and DIS229. 
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This heterogeneity had originally been noted in an American family that is 
part of the series of families being reported here12. Since that report, we have 
observed six other families that also fail to show linkage; there are no clinical 
features that clearly let us differentiate linked from unlinked subtypes. The 
haplotype results for these six new families are shown in Figure 1. The 
multipoint analysis was done by using the interlocus distances estimated 
above. The origin was set arbitrarily at D1S245, and the LOD scores were 
calculated at ~0.3-cM intervals for each family. All sets of scores from the 
rolling-point multipoint analysis were used the multiple HOMOG analyses. 
However, only the results of the heterogeneity analysis for the LOD scores 
between D1S556 to D1S227 are summarized in Table 2, since it was evident 
that the USH2A gene could not conceivably lie outside this region. 
Table 2. Linkage heterogeneity analysis of Usher type Π family data for 
chromosome lq41 markers. 
Hypothesis 
H2 
H, 
Maximum Log 
Likelihood 
99.89 
50.68 
Estimation of 
α 
.875 
(0) 
Distance from S2< 
.075 (S237-S229) 
.065 (S556-S237) 
(.50) 
Components of χ2 
Source df Likelihood ratio 
H2 vs H, (heterogeneity) 
H, vs H0 (linkage) 
H2 vs H„ (total) 
1 98.41 
1 101.37 
2 199.78 
2.3 x 102' 
1.03 x 1022 
2.40 x 10J1 
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Figure 2. Linkage data graphed as isometric lines at various LOD likelihood 
values. LOD scores for all Usher type II families were calculated using 
the multipoint option of LINKAGE for the markers DIS556, D1S237, 
D1S229, and D1S227 and input into the HOMOG program. The values 
graphed here were calculated by HOMOG for values of a between 0 and 
1.0, at .1 increments. The thicker solid line, which corresponds to the 
isometric at a LOD of -3 below the maximal LOD score, is totally 
contained within the brackets for D1S237-D1S229, illustrating that the 
USH2 gene on chromosome lq can be placed between these markers, 
with > 1,000:1 odds of confidence. Thus, the replacement ofUSH2A gene 
can be made with confidence, despite the fact that considerable genetic 
heterogeneity is present in the sample of families analyzed. 
Both the hypothesis of no linkage (H0) and that of linkage with no 
heterogeneity (H,), are rejected, but the hypothesis of linkage with 
heterogeneity (H2) is not rejected. The best estimate of the fraction of linked 
families is .875. Obviously, the converse of this is that 12.5% of Usher type 
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II families fail to show linkage with the lq41 markers. Given this 
heterogeneity, the best location of the USH2 gene was calculated as being 7.5 
cM from D1S245, between the markers D1S237 and D1S229. Note, however, 
that the best position of the USH2A gene shifts to between D1S556 and 
D1S237 if heterogeneity is rejected. This raised the issue of the degree of 
confidence with which the USH2A gene can be placed into the D1S237 -
D1S229 segment. To address this, we plotted the LOD score distribution 
calculated by HOMOG, in an isobar format as shown in Figure 2. 
The x-axis and γ-axis are, respectively, the location on chromosome lq 
(shown here only for a limited location, namely, that between D1S556 and 
D1S227) and a, the proportion of linked families. The isobar lines represent 
constant levels of LOD scores as a function of both position and proportion 
of linked families. The maximum LOD score for the surface between D1S556 
and D1S237 is 95.30, a value 3.19 LOD units lower than the maximum value 
calculated between D1S237 and D1S229. 
The isometric for -3 LOD, which is shown as the more-solid line, does not 
infringe into either the D1S556-D1S237 segment or the D1S229-D1S227 
segment. Thus, it is reasonable to conclude that the USH2A gene lies 
between the markers D1S237 and D1S229 and that this placement can be 
made with a high degree of confidence, despite the complication of linkage 
heterogeneity. 
This conclusion is also supported by haplotype analysis. Four critical families 
are presented in Figure 3. Two families merit discussion. The first is family 
652, whose parents are second cousins. Their only affected child is 
heterozygous for D1S237, but the expectation is that any affected child would 
be homozygous for all near linked genes. Consequently, it is reasonable to 
explain this occurrence as due to a crossover between D1S237 and USH2A 
and to exclude the USH2A gene from the region centromeric to D1S237. 
An alternative explanation is that the Usher type II gene in the family is not 
linked to lq41. This possibility is reflected in the probability of linkage, 
which was calculated by HOMOG to be 0.70. Such a low probability of 
linkage is not unexpected for families showing a critical single crossover with 
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either the flanking markers. This poses a problem, since a crossover with 
D1S237 and not with D1S229 suggests placement of the USH2A gene 
telomeric to D1S237 and is thus a significant observation pointing to the 
distal side of D1S237 as the target region for future genetic and physical 
mapping. Unfortunately, the crossover with D1S237 also reduces the 
probability that the family is Usher type IIA and compromises the reliability 
of this family's data as mapping information. 
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Figure 3. Pedigrees of four critical families showing probable exclusion of the 
USH2A gene from the region proximal to DJS237 and distal to D1S229. 
The posterior probability of linkage calculated by HOMOG is also given 
for each family. Note that family 453 has a high probability of lq41 
linkage and that it supports exclusion of USH2A from the region 
proximal to D1S237. Two families (869 and 983) show that the USH2A 
gene cannot be distal to D1S229, and thus it does not lie in the same 
region as do TGFB2 and HLX1. Family 652 is consanguineous and 
supports the exclusion ofUSH2A centromeric to D1S237, by virtue of 
heterozygosity at that marker and its proximal neighbours. 
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Fortunately, a large family (453) was ascertained that consisted of two genetically 
independent sibships presumed to have the same Usher type II subtype because two 
of their members married and have had an affected child. Although a critical 
crossover occurred in one person, there is sufficient linkage data to keep the 
probability of linkage high (>.99), so that the exclusion of the USH2A gene from 
cenlromeric side of D1S237 can be made with good confidence. 
On the basis of this analysis, the distribution of families, by probability of linkage, 
is <01 , 7 families; .70-.90, 3 families; .90-.95, 16 families; and >.95, 42 families. 
Cytogenetic results 
One member of each of 38 Usher type II families showing linkage to 1 q41 markers 
has been karyotyped in an effort to detect one or more patients with a cytogenetic 
abnormality. The average band number seen was 525. The region specifically 
around lq41 was examined in detail, and no deletions, inversions, or translocations 
were seen. 
DISCUSSION 
The map of the region around lq41 has been updated. Data are presented that 
combine the Généthon map17 markers with the map of framework markers that had 
been previously published through the СЕРН collaboration2223. The order and 
distances determined in the present study agree well with that given in the Genome 
Data Base. 
The major problem in beginning with fine gene mapping of the USH2A gene is its 
genetic heterogeneity. It is estimated that -12.5% of families fail to show linkage 
with lq41. This fact complicates the search for the USH2A gene because families 
showing critical crossovers cannot be accepted with total confidence. 
Consequently, physical mapping strategies are employed with some hesitation unless 
other factors are present that enhance the likelihood of localization. One method of 
circumventing the problem of heterogeneity is to use only data from a population 
isolate. Unfortunately that cannot be the case here, since no isolate with Usher type 
IIA is known. As an alternative, we have elected to increase our sample size as 
much as possible, with the belief that the likelihood distribution calculated from a 
large sample would be less sensitive to effects of heterogeneity. Furthermore, a 
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large sample presents greater opportunities for a serendipitous observation that can 
be helpful in fine gene localization. Both factors were present in this study. The 
linkage analysis places the gene for Usher type IIA within an ~2.1-cM region 
flanked by the markers D1S237 and D1S229, with a high degree of confidence. 
While a small probability exists that the gene could be between D1S556 and 
D1S237, this location is contraindicated by haplotype analysis of at least one 
family. The data certainly rule out both TGFB2 and HLX1 as candidate genes, 
since TGFB2 is placed between D1S320 and PPOL and HLX1 is distal to TGFB2. 
The proposed location of USH2A is shown graphically in the ideogram for 
chromosome lq shown in Figure 4. 
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D1S414 
D1S70 
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Figure 4. Location of the markers on an ideogram of chromosome lq, with the 
placement of the USH2A gene indicated by the thick gray box. Three new 
markers -D1S419, D1S490, and D1S474- have not yet been typed in 
these families but could provide evidence for further sublocalization. 
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The genetic heterogeneity of Usher type II raises certain important scientific 
and clinical questions. For the purposes of clarity, the Usher type II gene 
linked to lq41 is designated USH2A, and the unlinked one has been labeled 
USH2B. A perusal of the clinical findings does not suggest any immediately 
obvious clinical symptomatology that would allow for a distinction of the two 
subgroups. It is tempting to speculate that the unlinked USH2B may be the 
gene responsible for Usher type III, commonly thought of as Usher syndrome 
with progressive hearing loss28'29. How the Usher type III phenotype relates to 
the Usher type II genes remains to be determined, and Usher type III may 
represent yet another gene. Audiologic and vestibular phenotypes are both 
relatively unsubtle and provide little opportunity for differentiation of the 
Usher type II subtypes. It may be, however, that ophthalmologic psychop-
hysical measures taken from either affected individuals or heterozygotes 
might provide clues to important phenotypic differences between the genes. 
Study of the effect in the heterozygotes is an important consideration because 
the disruption of retinal function may be too severe to allow for reliable 
differentiation in affected homozygotes. Differentiation of the subtypes by 
phenotypic examination may be critical in the localization of the USH2B 
gene, since now the only means of identifying such families is by virtue of 
the lack of linkage with chromosome lq41 markers, and more families will 
be needed if the gene is to be mapped to a segment as small as that to which 
USH2A has been mapped. A recognized phenotypic difference would also 
give greater assurance for correctly including critical Usher type II families in 
the fine mapping protocol for USH2A. 
None of the unlinked cases appear to come from a unique population. Three 
are from Sweden, one is from Spain, and the remainder are from the United 
States. Preliminary data (not shown) do not indicate linkage with the known 
location for a Usher type I -namely, chromosomes 1 lp, 1 lq, or 14q - and a 
genome search is underway. 
It has been surprising to find that Usher syndrome is the result of mutations 
in at least five different genes. These genes may be related and represent 
different forms of a gene family whose function is yet to be determined. 
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The findings presented here have important implications for the positional 
cloning of the Usher type IIA gene and focus our attention on D1S237 and 
D1S229 as initiation points for physical mapping experiments. YACs for 
D1S237 and D1S229 have been isolated, and the work to construct a contig 
for this region has begun (J. Sumegi, unpublished data). 
Note added in proof. — The gene for Usher syndrome III has been recently 
mapped to chromosome 3q30. The seven unlinked families presented here 
were typed for the same 3q markers, and five were found to be linked and 
two were unlinked. Of the five linked to 3q, four were from Sweden. 
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7 
SUMMARY AND CONCLUSIONS 

Summary and conclusions 
The Usher syndrome has an autosomal recessive pattern of inheritance and 
leads to the loss of two sensory functions, hearing and sight. It is fairly 
common and in about 50% of the cases, it probably forms the cause of deaf-
blindness in adulthood. How strongly invalidating this handicap is, becomes 
clear in all its magnitude when one comes into contact with the deaf-blind. 
In the nineteen eighties, the Department of Human Genetics of the Boys 
Town National Research Hospital, Omaha, Nebraska (Prof. Dr W.J. 
Kimberling), was the only genetic institute in the world that focused 
especially on achieving gene linkage and gene isolation for hereditary 
disorders with deafness as the most important characteristic. Although it is 
easier to arrive at a positive lod score for gene linkage in autosomal dominant 
sex-linked hereditary syndromes, it was decided to study this autosomal 
recessive hereditary syndrome in view of the gravity of the double sensory 
handicap and the relatively high incidence. An international project was 
needed to assemble the necessary 200 multi-affected families with various 
types of the Usher syndrome. The invitation from Boys Town for Nijmegen 
to participate, was accepted. The aim was to contribute to the isolation of the 
genes responsible for the Usher syndrome and to document the clinical 
symptoms of the Usher syndrome on the basis of the results of gene linkage 
in persons affected by the syndrome. 
Classification of the Usher syndrome into 3 types based on clinical 
observations, was in fact a reasonable working hypothesis, which required 
further support from gene linkage results. In this way it would be possible to 
test the existing clinical symptoms against the new clinical findings. In 
addition, a description could be made of the clinical course of the various 
types (including all the variations within the separate types) and of the 
differences between them. 
For organisational reasons during the first phase of the Nijmegen Usher 
project, priority was given to recruiting patients with hearing impairment and 
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the Usher syndrome, who according to the existing classification, were mainly 
suffering from type II or type III. In addition, a start was made to recruit 
patients with the Usher syndrome type I with congenital deafness for 
involvement in a later phase of the Nijmegen Usher project. In contrast with 
the Usher syndrome type II and type III, persons affected by type I are totally 
deaf from birth. This classification, based on clinical observations, is 
presented schematically in the Introduction. 
Chapter 2 describes the separate findings in 10 obligate carriers of Usher type 
2A who underwent extensive audiovestibular and ophthalmological testing. 
Audiological tests showed slight perceptive hearing loss at the frequencies 
0.25 - 8 kHZ in all the carriers, even after correction for possible age-related 
hearing loss. At the frequencies 0.25 - 0.5 kHZ, the loss was significant. 
Over the past few years, the idea has been put forward that carriers of 
disorders with autosomal recessive hereditary congenital deafness are more 
susceptible to exogenic influences, such as noise trauma and ototoxic 
medication. This may also be the case in carriers of the gene for Usher type 
2A. 
A small number of the carriers of Usher type 2A had slight vestibular 
abnormalities, but these were of no clinical value for carrier detection. Except 
for subnormal electro-oculography (EOG) results in 5 out of the 10 carriers, 
no other striking abnormalities were observed during extensive 
ophthalmological testing. 
EOG testing was continued and an additional 10 carriers of Usher syndrome 
type I and a group of carriers of other tapetoretinal dystrophies were tested. 
The latter group comprised patients with retinitis pigmentosa (N=32), 
neuronal ceroid lipofuscinosis (N=6), the Senior syndrome (N=2) and 
choroideremia (N=17). Subnormal EOG values were seen in 30% of the total 
group of Usher carriers. In the carriers of retinitis pigmentosa, the cause of 
visual impairment in Usher patients, there was a trend towards subnormal 
EOG results. Carriers of neuronal ceroid lipofuscinosis and carriers of 
choroideremia had normal EOG results. In the latter disorder, the EOG Lp Dt 
164 
Summary and conclusions 
ratio appeared to decrease with increasing age. It could be concluded that 
subnormal EOG results form an indication of carriership in family members 
of patients with tapetoretinal dystrophies. This was particularly the case for 
the Usher syndrome. 
In chapter 3. the hearing loss in 23 patients with Usher syndrome type 2A is 
described. In 13 patients for whom a number of serial audiograms were 
available, the course of the hearing loss could be established. The follow-up 
period of these measurements ranged from 9 to 32 years. A regression 
analysis was performed on the binaural pure tone average (BPTA) in relation 
with age, to investigate whether there was any 'significant' progression in the 
hearing loss. Significant progression was revealed in 3 patients. An analysis 
of the variation in the Annual Threshold Increase (ATI) showed indications 
of significant clinical heterogeneity. Hearing loss was either stable or 
progressive. An analysis was also performed on the Annual Threshold 
Increase (ATI) of the patients with 'type III' and progressive hearing loss 
described in the literature, several of whom have recently been linked to 
chromosome 3q (USH3 locus). A similar analysis of our progressive Usher 
2A patients and these patients did not demonstrate any significant 
heterogeneity of progression of the hearing loss. We concluded that a patient 
with progressive hearing loss can have the USH2A genotype or the USH3 
genotype. 
Chapter 4 presents the ophthalmological findings in 37 Usher type 2A 
patients, 24 familial cases and 13 isolated cases. Striking ophthalmological 
variability was observed. The corrected visual acuity was set out against age 
and revealed a decrease in visual acuity with increasing age. The influence of 
cataract formation is discussed. The findings seem to be useful for genetic 
counselling. In addition, striking differences in visual acuity were observed 
between affected persons in one family. 
Narrowing of the visual fields to tunnel vision was observed with increasing 
age. The various fundus aspects were classified into two types. Type A: bone 
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corpuscles in all quadrants and narrow vessels. Type B: other fundus 
abnormalities. The proportion of type A fundus increased with increasing age. 
Colour vision testing on Usher patients and other retinitis pigmentosa patients 
is also described in this chapter. The influence of cystoid macula oedema on 
colour vision was investigated. To begin with, cystoid macula oedema had 
more effect on visual acuity than on colour vision. The familial incidence of 
cystoid macula oedema was striking. 
In chapter 5, the light-microscopic findings in the inner ear of an 84-year-old 
Usher type I patient are described. The histopathological abnormalities were: 
degeneration of the organ of Corti, which was most marked in the basal turn, 
degeneration of the cochlear neurons in all the turns and a marked loss of 
spiral ganglia in both cochleae. Endolymphatic hydrops of unknown origin 
was also observed. 
Chapter 6 first describes the American gene linkage results obtained in 68 
informative families out of the 220 available Usher type II families. The 
families, 55 multiplex and 13 simplex families, came from the Netherlands, 
the USA, Sweden, England, Ireland, Italy, Columbia and Spain. Analysis of 
the marker data localised the gene for Usher type 2A in a 2.1 -cM segment 
between known markers on chromosome 1. Six new families (not from the 
Netherlands) were also identified, who did not link to chromosome 1. These 
families therefore received the preliminary classification of Usher type 2B. 
The percentage of Usher type II families who are not expected to link to 
chromosome 1 is estimated to be 12.5%. USH2B was not identified in any of 
the Dutch families. 
The choroideremia-like (CHML) gene was discovered in Nijmegen on the 
chromosome lq31-qter region of chromosome l1,2, where the Usher type 2A 
gene is also localised. As both choroideremia and the Usher syndrome belong 
to the tapetoretinal dystrophies, we investigated the possible role of the 
CHML gene in the pathogenesis of Usher type II. The findings in 9 Dutch 
isolated Usher type II patients and in 10 Danish patients revealed that the 
CHML gene is not involved in Usher syndrome type II. 
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For the sake of completeness, it should also be mentioned that all the Usher 
syndrome patients described in this thesis underwent routine vestibular testing 
with a rotatory chair and electronystagmography to augment the clinical 
diagnosis. These research results have been analysed and submitted for 
publication, but are not included or discussed further in this thesis. 
The study described in this thesis could not be completed until the results of 
individual gene linkage became available. In individual cases, the data 
obtained could not provide solid evidence, because the gene for Usher 
syndrome type 2A has not yet been identified. However, it is gradually 
becoming clear that world-wide, the majority of affected persons with the 
clinical diagnosis of Usher syndrome type II are in fact suffering from type 
2A and only exceptionally from type 2B3. 
For many years, there has been doubt about the existence of Usher type III. 
At the beginning of 1995, the first Finnish reports appeared on gene linkage 
to chromosome 3 in Usher type III patients4 with progressive hearing loss. 
This made it possible to perform separate gene linkage studies in Boys Town 
to investigate whether the Dutch patients with type 2A should be reclassified 
as having type III. The study (not mentioned in the previous chapters) 
showed that so far, none of the Dutch Usher 2A families have linked to the 
locus for Usher type III. This observation once again underlines the value of 
the finding in Chapter 3 that in contrast with the existing classification, the 
hearing loss in Usher 2A can be progressive. Therefore, on the basis of these 
findings, the existing clinical description of Usher type II, particularly type 
2A, should be revised. 
The clinical findings in this study on Usher type II together with those from 
the second phase of the project on Usher type I, it will make possible to 
describe the course of hearing and visual impairment. In this way we might 
be able to establish whether there is any overlap in the degree of hearing loss 
and whether there is any characteristic difference in the course of visual 
impairment. 
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In 1995, it was found that myosin VII A was the missing gene in Usher type 
IB patients6. This step provided the opportunity to examine whether myosin 
VII A is present in the retina and in the cochlea, in order to leam more about 
the pathophysiology of the syndrome. Attempts to search for the gene for 
Usher type IB were based on a candidate gene known from murine genetics 
that was found in the Shaker mouse7. A competition arose between the 
various genetic laboratories in Omaha and Paris in the search for the Usher 
IB gene, which unavoidably delayed the possibility of identifying the gene 
responsible for Usher type II during the study period. Nevertheless, on the 
basis of an extensive group of Dutch multi-affected families and isolated 
cases, and on the basis of the gene linkage results obtained in the meantime, 
we were able to comply with the study assignment of further describing the 
clinical symptoms of Usher type 2A. 
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Het Usher syndroom is een autosomaal recessief overervende aandoening, die 
leidt tot verlies van twee zintuigfuncties, het horen en het zien. Het Usher 
syndroom komt relatief vaak voor en zou in ongeveer 50% van de gevallen 
de oorzaak voor de doofblindheid op volwassen leeftijd zijn. Hoe sterk 
invaliderend deze handicap is wordt in zijn omvang invoelbaar wanneer men 
in contact komt met de doofblinden. 
De afdeling Human Genetics van het Boys Town National Research Hospital, 
Omaha, Nebraska (Prof. Dr W.J. Kimberling) was in het midden van de 
tachtiger jaren het enige genetische instituut in de wereld dat zich vooral 
richtte op het bereiken van genkoppeling en genisolatie voor erfelijke 
ziektebeelden met doofheid als belangrijk kenmerk. Alhoewel het eenvoudiger 
is om bij autosomaal dominant en geslachtsgebonden overervende 
ziektebeelden tot genkoppeling te komen, werd gezien de ernst van de 
dubbele zintuiglijke handicap en de relatief hoge incidentie, er toch in die 
periode voor gekozen om dit autosomaal recessieve overervende ziektebeeld 
te gaan bestuderen. Een internationale samenwerking was nodig om de 
benodigde 200 families met meer dan 1 aangedane persoon met verschillende 
typen van het Usher syndroom bijeen te brengen. De uitnodiging van Boys 
Town om hierin vanuit Nijmegen bij te dragen werd aanvaard. Het doel was 
om bij te dragen aan de isolatie van de genen verantwoordelijk voor het 
Usher syndroom en om de erbij passende klinische beelden van het Usher 
syndroom te omschrijven op basis van bij lijders aan het syndroom 
gerealiseerde genkoppelingsresultaten. 
De op klinische waarnemingen gebaseerde indeling van het Usher syndroom 
in 3 typen was feitelijk een redelijke werkhypothese, die nader onderbouwd 
diende te worden door genkoppelingsresultaten. Aldus zou het mogelijk 
worden de gehanteerde klinische beelden te toetsen aan de nieuwe klinische 
bevindingen. Evenzo zou het mogelijk worden om het klinisch beloop van de 
verschillende typen in zijn variatie binnen het afzonderlijke type te 
beschrijven alsook om het verschil tussen de verschillende typen van het 
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Usher syndroom te beschrijven. 
Omwille van organisatorische redenen werd tijdens de eerste fase van het 
Nijmeegse Usher project voorrang verleend aan het betrekken bij deze studie 
van de slechthorende lijders aan het Usher syndroom, die volgens de 
geldende indeling vooral een type II en type III zouden hebben. Tevens werd 
een begin gemaakt om ook lijders aan Usher syndroom type I met een 
aangeboren doofheid bij dit onderzoek te betrekken met het oog op het latere 
vervolgproject van dit Nijmeegse Usher project. In tegenstelling tot Usher 
syndroom type II en III zijn lijders aan het type I sedert hun geboorte 
volledig doof. Deze op klinische waarnemingen gebaseerde indeling is 
schematisch in de inleiding van deze dissertatie vermeld. 
In hoofdstuk 2 worden de afzonderlijke bevindingen van uitgebreid 
audiovestibulair en oogheelkundig onderzoek bij 10 obligate carriers van het 
Usher type 2A beschreven. Bij uitgebreid audiologisch onderzoek wordt een 
gering perceptief gehoorverlies bij de geteste frequenties 0.25 - 8 kHz bij alle 
carriers vastgesteld, ook na correctie voor het eventueel bij de leeftijd te 
verwachten gehoorverlies. Bij de frequenties 0.25 - 0.5 kHz is dit verlies 
significant. 
De laatste jaren doet zich de gedachte voor, dat carriers van autosomaal 
recessief overervende aangeboren doofheden meer bevattelijk zijn voor 
exogene factoren, zoals lawaaibeschadiging en ototoxische medicatie. Dit zou 
ook bij carriers van het gen voor Usher type 2A het geval kunnen zijn. 
Een klein aantal van de onderzochte Usher type 2A carriers vertoont lichte 
vestibulaire afwijkingen, echter deze zijn klinisch niet van betekenis voor 
carrierdetectie. Behoudens een subnormaal electro-oculografie (EOG) uitslag 
bij 5 van de 10 carriers, worden geen andere opvallende afwijkingen 
vastgesteld bij uitgebreid oogheelkundig onderzoek. 
Het EOG onderzoek werd voortgezet en aanvullend werden nog 10 carriers 
van het Usher syndroom type I, alsook carriers van andere tapetoretinale 
dystrofieën onderzocht; te weten: retinitis pigmentosa (N=32), neuronale 
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ceroid lipofuscinosis (N=6), Senior syndroom (N=2) en choroideremia 
(N=17). Van de totale groep Usher carriers toont 30% subnormale EOG 
waarden. Bij carriers van retinitis pigmentosa, de oorzaak van slechtziendheid 
bij Usher patiënten, bestaat er een trend tot een subnormaal EOG. Carriers 
van neuronale ceroid lipofuscinosis tonen een normaal EOG. Zo ook de 
carriers van choroideremia, maar bij deze laatste aandoening lijkt de EOG 
Lp/Dt ratio te dalen bij toenemende leeftijd. Geconcludeerd wordt dat een 
abnormaal EOG een indicator kan zijn van een carriërschap bij familieleden 
van patiënten met tapetoretinale dystrofieën. Dit geldt in het bijzonder voor 
het syndroom van Usher. 
In hoofdstuk 3 wordt het gehoorverlies bij 23 patiënten van het Usher 
syndroom type 2A beschreven. Bij 13 patiënten van wie meerdere 
audiogrammen beschikbaar zijn wordt het verloop van het gehoorverlies 
bestudeerd. De follow-up periode van deze metingen loopt uiteen van 9 tot 32 
jaar. Een regressie analyse van de 'binaural pure tone average' (BPTA) ten 
opzichte van de leeftijd is bepaald om na te gaan of er sprake is van een 
'significante' progressie van het gehoorverlies. Bij 3 patiënten wordt een 
significante progressie aangetoond. Een analyse van de variantie van de 
Annual Threshold Increase (ATI) geeft aanwijzingen voor significante 
klinische heterogeniteit. Het gehoorverlies is namelijk of stabiel of 
progressief. Ook wordt de Annual Threshold Increase (ATI) van de in de 
literatuur beschreven 'type III' patiënten met een progressief gehoorverlies, 
waarvan enkele recentelijk gekoppeld zijn op chromosoom 3q (USH3 locus) 
geanalyseerd. Een soortgelijke analyse als boven genoemd bij onze 
progressieve Usher 2A patiënten en deze patiënten kan geen significante 
heterogeniteit van progressie van het gehoorverlies aantonen. Geconcludeerd 
wordt dat een patiënt met een progressief gehoorverlies zowel een USH2A 
genotype als USH3 genotype kan hebben. 
Hoofdstuk 4 presenteert de oogheelkundige bevindingen bij 37 Usher type 2A 
patiënten, 24 familiaire en 13 geïsoleerde gevallen. Een opmerkelijke 
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oogheelkundige variabiliteit wordt beschreven. Het gecorrigeerde 
gezichtsvermogen wordt uitgezet tegen de leeftijd en vertoont een afname bij 
het vorderen van de leeftijd. De invloed van cataract hierop wordt besproken. 
De bevindingen lijken bruikbaar bij 'genetic counseling'. Tevens worden 
opmerkelijke verschillen in gezichtsvermogen vastgesteld tussen lijders van 1 
gezin. 
Een vernauwing van het gezichtsveld tot kokervisus wordt vastgesteld bij 
toename van de leeftijd. De diverse fundusaspecten werden geklassificeerd in 
twee typen. Type A: uitgesproken beenbalkjes in alle kwadranten en nauwe 
vaten. Type B: andere fundusafwijkingen. Het aandeel van type A fundus 
neemt toe met het vorderen van de leeftijd. 
Kleurenzientest resultaten bij Usher patiënten worden ook in dit hoofdstuk 
beschreven. De invloed van cystoïd macula oedeem op het kleurenzien wordt 
onderzocht. Het cystoïd macula oedeem heeft in eerste instantie een effect op 
het gezichtsvermogen en veel minder op het kleurenzien. Opvallend is het 
familiair voorkomen van cystoïd macula oedeem. 
In hoofdstuk 5 worden de lichtmicroscopische bevindingen van het binnenoor 
van een 84 jarige Usher type I patiënt beschreven. De histopathologische 
afwijkingen zijn: degeneratie van het orgaan van Corti, die het meest 
uitgesproken is in de basale winding, degeneratie van cochleaire neuronen in 
alle windingen en een uitgesproken verlies van spirale ganglia in beide 
cochleae. Ook is een endolymphatische hydrops van onbekende origine 
vastgesteld. 
In hoofdstuk 6 worden allereerst de Amerikaanse genkoppelingsresultaten 
beschreven van 68 informatieve families van 220 beschikbare Usher type II 
families. De families, 55 multiplex en 13 simplex families, zijn afkomstig uit 
Nederland, VS, Zweden, Engeland, Ierland, Italië, Colombia en Spanje. 
Analyse van marker data lokaliseert het gen voor Usher type 2A in een 
2.1 -cM gebied tussen bekende markers op chromosoom 1. Ook werden 6 
nieuwe niet uit Nederland afkomstige families welke niet koppelen op 
172 
Samenvatting en conclusies 
chromosoom 1 geïdentificeerd. Deze families worden daarom voorlopig 
geklassificeerd als Usher type 2B. Het aandeel Usher type II families welke 
niet koppelen op chromosoom 1 wordt geschat op 12.5%. In geen van de 
Nederlandse families werd USH2B vastgesteld. 
In Nijmegen is het choroideremia-like (CHML) gen ontdekt op chromosoom 
lq31-qter regio van chromosoom l1,2, waar ook het Usher type 2A gen 
gelokaliseerd is. Aangezien zowel choroideremia en het Usher syndroom 
behoren tot de tapetoretinale dystrofieën werd de mogelijke rol van het 
CHML gen op de pathogenese van Usher type II onderzocht. De bevindingen 
bij 9 Nederlandse geïsoleerde Usher type II patiënten en 10 Deense patiënten 
lieten zien dat het CHML gen niet betrokken is bij Usher syndroom type II. 
Hier wordt volledigheidshalve vermeld dat alle in deze dissertatie beschreven 
patiënten met het Usher syndroom ter onderbouwing van de klinische 
diagnose een routinematig uitgevoerd vestibulair onderzoek met behulp van 
draaistoel en electronystagmografie hebben ondergaan. Deze 
onderzoeksresultaten zijn weliswaar bewerkt maar zijn buiten deze dissertatie 
gelaten en worden daarom hier niet verder besproken. 
De afronding van het in dit proefschrift beschreven onderzoek moest wachten 
op het verkrijgen van de genkoppelingsresultaten voor de individuele 
gevallen. Bovendien kan in het individuele geval uit de verkregen resultaten 
geen volledig bewijs verkregen worden omdat het gen van het Usher 
syndroom type 2A nog niet geïdentificeerd is. Gaandeweg wordt echter 
duidelijk dat wereldwijd de meeste lijders met klinisch het Usher syndroom 
type II lijden aan type 2A en deze slechts bij uitzondering aan type 2B 
lijden3. 
Lange tijd bleef onzeker of er wel een type III Usher syndroom zou bestaan. 
Toen begin 1995 de eerste berichten uit Finland kwamen over genkoppeling 
op chromosoom 3 bij het Usher syndroom type III4 aldaar met een progressief 
gehoorverlies5 ontstond de mogelijkheid om afzonderlijk in het Boys Town 
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National Research Hospital te testen of mogelijk toch als type 2A 
geklasseerde Nederlandse Usher patiënten alsnog getypeerd zouden moeten 
worden als type III. Uit dit niet in de vorige hoofdstukken vermelde 
onderzoek is gebleken dat tot nu toe geen van deze Nederlandse Usher 2A 
families koppelde voor de locus van Usher type III. Hetgeen nogmaals de 
waarde van de bevinding in hoofdstuk 3 onderstreept dat het gehoorverlies bij 
het Usher 2A syndroom in tegenstelling tot de tot nu toe geldende 
klassificatie wel progressief kan zijn. De tot nu toe geldende klinische 
beschrijving voor het Usher syndroom type II met name type 2A moet 
daarom op basis van deze bevinding herzien worden. 
De klinische bevindingen van deze studie over het Usher syndroom type II 
maken het mogelijk om samen met de klinische bevindingen uit het 
vervolgproject over Usher syndroom type I het afzonderlijke verloop van het 
gehoorverlies en het visusverlies in de loop der tijd te beschrijven. Op deze 
manier kan worden nagegaan of er overlap bestaat in de mate van het 
gehoorverlies en in hoeverre er al dan niet een kenmerkend verschil bestaat in 
het verloop van het visusverlies. 
In 1995 lukte het vast te stellen dat myosine VIIA het gen is dat ontbreekt bij 
lijders aan het Usher syndroom type IB6. Een dergelijke stap maakt het 
mogelijk te zoeken naar het bestaan van myosine VIIA in de retina alsook in 
de cochlea om aldus de pathofysiologie van het ziektebeeld beter te leren 
kennen. Bij het zoeken naar het gen voor Usher IB syndroom werd uitgegaan 
van een in de muizengenetica bekend geworden kandidaatgen dat gevonden 
was bij de Shaker muis7. De competatieve zoektocht naar het Usher IB gen 
van de genetische laboratoria in Omaha en Parijs remde onvermijdelijk de 
mogelijkheden tijdens de onderzoeksperiode van deze promotiestudie om in 
Omaha een nauwere genkoppeling en het gen voor het Usher syndroom type 
2A te kunnen vinden. Desondanks was het mogelijk om op grond van een 
omvangrijke groep Nederlandse families met meer dan 1 lijder en geïsoleerde 
lijders aan het Usher type II en op grond van de inmiddels bereikte 
genkoppelingsresultaten te voldoen aan de gestelde opgave om het klinisch 
beeld van het Usher syndroom type 2A nader te omschrijven. 
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1992 is A. van Aarem arts-assistente in opleiding tot Keel-, Neus- en Oorarts 
in het Academisch Ziekenhuis te Nijmegen. 
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Stellingen behorend bij het proefschrift: 
Heterogeneity in the Usher Syndrome 
A. van Aarem 
1. Het gehoorverlies bij lijders aan het syndroom van Usher type 2A kan 
progressief zijn en is in dat geval vooralsnog niet te onderscheiden van 
het gehoorverlies bij het syndroom van Usher type III. 
(dit proefschrift) 
2. Het beeld van de oogfundus bij het syndroom van Usher type 2A wordt 
gekenmerkt door een grote variabiliteit. 
(dit proefschrift) 
3. Met uitgebreid audiovestibulair en oogheelkundig onderzoek is het 
dragerschap van het Usher 2A gen niet zeker klinisch vast te stellen, 
al wijst een subnormaal electro-oculogram wel in die richting. 
(dit proefschrift) 
4. Het voorkomen van cystoïd macula-oedeem bij retinitis pigmentosa 
heeft voornamelijk invloed op de gezichtsscherpte en niet op het 
kleurenzien. 
(dit proefschrift) 
5. De histopathologische bevindingen in het binnenoor bij het syndroom 
van Usher zijn: degeneratie van het orgaan van Corti, atrofie of 
degeneratie van de stria vascularis, degeneratie van de spirale ganglia 
en een niet afwijkend vestibulum. 
(dit proefschrift) 
6. Het syndroom van Usher type 2A komt in Nederland omstreeks negen 
maal zo vaak voor als het syndroom van Usher type 2B. In ons land 
wordt het syndroom van Usher type III nauwelijks aangetroffen. 
7. Voor lijders aan het syndroom van Usher met totale doofheid kan een 
cochleaire implant een belangrijk hulpmiddel zijn. De implant dient bij 
voorkeur op jonge leeftijd te worden aangebracht. 
8. Het radiologisch vervolgen van een eenzijdig acusticusneurinoom in de 
brughoek is alleen verantwoord als de therapiemogelijkheden hierdoor 
niet worden beperkt. 
9. De mitochondriële overervingswijze kan oorzaak zijn van een 
schijnbaar X-linked overervende, niet-syndromale vorm van 
progressieve perceptieve slechthorendheid. 
10. Autosomaal recessief, niet-syndromaal overervende vroegkinderlijke 
slechthorendheid of doofheid wordt waarschijnlijk veroorzaakt door 
enige tientallen verschillende genen. 
11. Het wegvallen van de baroreceptorreflex na dubbelzijdige chirurgische 
verwijdering van glomustumoren kan invaliderend zijn voor de patiënt. 
12. Syncope kan het eerste symptoom van een hoofd-halstumor zijn. 
13. Voor het Nederlands taalgebied verdient de term "cervico-faciale 
chirurgie" de voorkeur boven de term "Hoofd-Halschirurgie". 
14. De doof-blindheid voor individuele noden die men bij sommige 
bestuurders aantreft, kan beschouwd worden als een maatschappelijke 
vorm van het syndroom van Usher. 



